

# Journal of Stroke and Cerebrovascular Diseases

## Risk factors for post-stroke shoulder pain: a systematic review and meta-analysis

--Manuscript Draft--

<b>Manuscript Number:</b>	JSCVD-D-19-01036R2
<b>Article Type:</b>	Review Article (invitation only)
<b>Section/Category:</b>	Neurology
<b>Keywords:</b>	stroke; Rehabilitation; shoulder pain, systematic review; risk.
<b>Corresponding Author:</b>	Rich J Holmes, MSc PT Western Sussex Hospitals NHS Foundation Trust Chichester, UNITED KINGDOM
<b>First Author:</b>	Rich J Holmes, MSc PT
<b>Order of Authors:</b>	Rich J Holmes, MSc PT Kara J McManus, BSc PT Christina Koulouglioti, PhD Beverley Hale, EdD
<b>Abstract:</b>	<p><b>Objective:</b> To identify the risk factors identified within one month post-stroke that predict the onset of post-stroke shoulder pain (PSSP) within the first year after stroke.</p> <p><b>Methods:</b> Five databases, (AMED, CINAHL, EMBASE, Medline, PubMed) were searched from inception to April 2019. Prospective cohort studies that measured a potential risk factor for post-stroke shoulder pain within the first month after stroke were included. Two authors independently reviewed and selected articles for inclusion. Risk of bias was assessed using the Quality in Prognosis Studies tool. Data extracted included raw data for odds ratio (OR) calculations, definition and measurement of pain, study limitations and baseline characteristics of participants. The review was conducted following PRISMA guidelines.</p> <p><b>Results:</b> Nine articles were retrieved that met the inclusion criteria, and six presented data to use in meta-analysis. Fifty-four different factors were identified as potential risk factors. Meta-analysis was possible for four factors; sex (OR 0.93, CI 0.75-1.15), laterality (OR 0.78, CI 0.59-1.05), diabetes (OR 2.09, CI 1.16-3.78), and history of shoulder pain (OR 2.78, CI 1.29-5.97). Reduced motor function in the upper limb was also identified as a significant risk factor through qualitative synthesis.</p> <p><b>Conclusions:</b> Reduced motor function in the upper limb, diabetes, and a history of shoulder pain were identified as significant risk factors for the development of PSSP within the first year after stroke. Recommendations to standardise future studies in this area have been made and it is suggested that defining subtypes of PSSP may aid future interventional studies.</p>

**Title:**

**Risk factors for post-stroke shoulder pain: a systematic review and meta-analysis**

**Running head:**

***Risk Factors for Post-Stroke Shoulder Pain***

**Keywords:**

stroke; Rehabilitation; shoulder pain, systematic review; risk.

**Authors:**

Rich J. Holmes, MSc<sup>1</sup>, richard.holmes@wsht.nhs.uk

Kara J. McManus, BSc<sup>1</sup>, kara.mcmanus@wsht.nhs.uk

Christina Koulouglioti, PhD<sup>2</sup>, christina.koulouglioti@wsht.nhs.uk

Beverley Hale, EdD<sup>3</sup>, [B.Hale@chi.ac.uk](mailto:B.Hale@chi.ac.uk)

1. Physiotherapy Department, Western Sussex Hospitals NHS Foundation Trust, Chichester, West Sussex, UK. Tel: (+44) 01243 831712
2. Research and Development Department, Western Sussex Hospitals NHS Foundation Trust, Chichester, West Sussex, UK. Tel: (+44) 01243 788122 ext 85627
3. Institute of Sport, University of Chichester, West Sussex, UK. Tel: (+44) 01243 816347

**Grant support:**

This research was undertaken as part of a Clinical Improvement Scholarship by Rich Holmes. Funding for the scholarship was gratefully received from Health Education Kent, Surrey and Sussex to support backfill costs.

**Conflicts of interest:**

Funding received from Health Education Kent, Surrey and Sussex was to support backfill costs only and the organisation had no input into the research topic, content or design. We have no other conflicts of interest to declare.

**Corresponding author:**

Rich Holmes

Extended Scope Physiotherapist in Spasticity Management

Physiotherapy Department

Western Sussex Hospitals NHS Foundation Trust

St Richard's Hospital

Spitalfield Lane, Chichester, UK, PO19 6SE

Tel: (+44) 01243 831712

Email: [richard.holmes@wsht.nhs.uk](mailto:richard.holmes@wsht.nhs.uk)

Rich Holmes  
Physiotherapy Department  
St Richard's Hospital  
Western Sussex Hospitals NHS Trust  
Chichester, West Sussex, UK  
PO19 6SE  
Richard.holmes@wsht.nhs.uk

Prof. Biller  
Editor  
*Journal of Stroke & Cerebrovascular Diseases*

February 11<sup>th</sup>, 2020

Dear Prof Biller:

Thank you for the opportunity to resubmit our manuscript entitled "**Risk Factors for Post-Stroke Shoulder Pain: A Systematic Review and Meta-analysis**" for consideration. We are again grateful to the reviewers for taking the time to reconsider our revisions.

We appreciate the reviewer's comments regarding the improved clarity the revisions have made. There was a further revision recommended:

*Please add that correlates of PSSP were beyond the scope of this paper and include as a limitation in the Discussion.*

We are grateful for the reviewer's comment and have added the recommended statement 'consequently correlates of PSSP were beyond the scope of this study' on line 105. However, given that we have made a number of references in the text as to why correlates were not included in the current study, we feel it would confuse the reader to say we then considered this lack of inclusion a limitation of the study. As our aim in the study was 'to identify the potential risk factors measured within the first month after stroke that predicted the onset of shoulder pain within the first year after stroke' we feel the inclusion of correlates would confound the results. We have therefore not added this to the limitation section.

We hope that the amendment is sufficient and that our justification for not including in the limitations section is clear. The revised manuscript has been appended and we have highlighted the revision on line 105 in yellow.

Thank you for your reconsideration of this manuscript.

Sincerely,



Rich Holmes, MSc MCSP  
Extended Scope Physiotherapist  
Western Sussex Hospitals NHS Trust

1 **Risk Factors for Post-Stroke Shoulder Pain: A Systematic Review and Meta-**  
2 **analysis**

3  
4 **Abstract**

5 **Objective:** To identify the risk factors identified within one month post-stroke that  
6 predict the onset of post-stroke shoulder pain (PSSP) within the first year after  
7 stroke.

8 **Methods:** Five databases, (AMED, CINAHL, EMBASE, Medline, PubMed) were  
9 searched from inception to April 2019. Prospective cohort studies that measured a  
10 potential risk factor for post-stroke shoulder pain within the first month after stroke  
11 were included. Two authors independently reviewed and selected articles for  
12 inclusion. Risk of bias was assessed using the Quality in Prognosis Studies tool.  
13 Data extracted included raw data for odds ratio (OR) calculations, definition and  
14 measurement of pain, study limitations and baseline characteristics of participants.  
15 The review was conducted following PRISMA guidelines.

16 **Results:** Nine articles were retrieved that met the inclusion criteria, and six  
17 presented data to use in meta-analysis. Fifty-four different factors were identified as  
18 potential risk factors. Meta-analysis was possible for four factors; sex (OR 0.93, CI  
19 0.75-1.15), laterality (OR 0.78, CI 0.59-1.05), diabetes (OR 2.09, CI 1.16-3.78), and  
20 history of shoulder pain (OR 2.78, CI 1.29-5.97). Reduced motor function in the  
21 upper limb was also identified as a significant risk factor through qualitative  
22 synthesis.

23 **Conclusions:** Reduced motor function in the upper limb, diabetes, and a history of  
24 shoulder pain were identified as significant risk factors for the development of PSSP  
25 within the first year after stroke. Recommendations to standardise future studies in  
26 this area have been made and it is suggested that defining subtypes of PSSP may  
27 aid future interventional studies.

28 **Introduction**

29 Post-stroke shoulder pain (PSSP) is a common and often debilitating consequence  
30 of stroke. Wide variations of incidence have been reported in the literature  
31 dependent on the patient cohort and methodology used. Most recent studies have  
32 found an incidence rate of between 18-22% at 3-4 months after stroke onset<sup>1-3</sup> with a  
33 slight reduction at 1 year post-stroke to between 6-21%.<sup>3,4</sup> Lindgren et al<sup>2</sup> reported  
34 that 73% of patients with PSSP reported they had pain daily whilst a further 11%  
35 reported constant pain, and 45% required some form of analgesic medication.

36

37 PSSP is known to negatively impact on a person's ability to carry out activities of  
38 daily living, such as walking and dressing,<sup>2</sup> and limit their ability to participate in  
39 leisure activities.<sup>5</sup> Furthermore it has been shown to be associated with reduced  
40 quality of life<sup>6,7</sup> as well as having a direct impact on mood.<sup>5</sup> Barlak et al<sup>8</sup> also  
41 reported a significantly longer stay in rehabilitation for patients with PSSP.

42

43 There is therefore a need to limit the impact of this common consequence of stroke  
44 through robust prevention strategies and effective treatment modalities. However,  
45 difficulties arise due to the complex and multifactorial nature of PSSP.<sup>9</sup> A large  
46 variety of possible aetiologies are described in the literature including  
47 musculoskeletal disorders such as rotator cuff dysfunction, bursitis, adhesive  
48 capsulitis, and impingement, as well as neurogenic problems such as spasticity,  
49 central hypersensitivity and complex regional pain syndrome.<sup>10</sup> Unsurprisingly this  
50 multitude of aetiologies has led to multiple interventions been suggested in the

51 literature. However, there seems to be little consensus on the implementation of  
52 some of these interventions<sup>11-13</sup> making assessment of their effectiveness difficult. A  
53 review by Li and Alexander<sup>14</sup> supported this when they found the evidence for  
54 treatments of PSSP to be lacking, though this should not be misinterpreted as  
55 evidence that treatments are ineffective.

56

57 The lack of consensus on best management makes prevention all the more  
58 important. However, to prevent PSSP we must first understand which patients are  
59 most at risk so that strategies can be put in place and regular assessments can be  
60 done to monitor any early developments of PSSP and limit the impact in the chronic  
61 stages. To answer this question, a number of often cited studies have explored  
62 factors that are correlated with PSSP such as subluxation,<sup>15</sup> spasticity,<sup>16</sup> and  
63 abnormal joint examination.<sup>17</sup> But due to the lack of repeated temporal measures  
64 these correlations do not show causation and the factors explored should not be  
65 interpreted as risk factors.

66

67 To date, reviews exploring PSSP have either been narrative in nature<sup>18</sup> or have  
68 focussed on factors that are correlated with PSSP.<sup>19</sup> Whilst these give an indication  
69 of factors closely linked to PSSP, they are limited by the variations in methodologies  
70 included and do not give a satisfactory answer to the matter of risk.

71

72 There is, therefore, a need to collate those studies investigating specifically risk and  
73 predictive factors that are effectively assessed and quantified using robust

74 prospective studies to see if there is agreement within the literature. The aim of this  
75 systematic review was to identify the potential risk factors measured within the first  
76 month after stroke that predicted the onset of shoulder pain within the first year after  
77 stroke.

78

79

## 80 **Methods**

81 To complete and report this review the Preferred Reporting Items for Systematic  
82 Reviews and Meta-Analyses (PRISMA) statement<sup>20</sup> was used.

83

### 84 *Search Strategy*

85 The search strategy was designed with the aid of a clinical librarian with input from  
86 the two lead authors (RH/KM). The databases AMED (1985 – April 2019), CINAHL  
87 (1937 – April 2019), EMBASE (1974 – April 2019), Medline (1946 – April 2019), and  
88 PubMed were used with no limitations applied. Variants of ‘stroke’, ‘shoulder pain’,  
89 and ‘risk factors’ were used as keywords and combined in the search strategy. The  
90 full search strategy can be viewed on the International Prospective Register of  
91 Systematic Reviews (PROSPERO: CRD42018110406) where this systematic review  
92 was registered. Further articles were sourced by hand-searching through the  
93 reference lists of key articles. The websites [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and  
94 [www.ukctg.nihr.ac.uk](http://www.ukctg.nihr.ac.uk) were regularly reviewed to check for any ongoing trials that  
95 may be relevant; however no articles were sourced using this method.

96

97 *Study Selection*

98 Studies were eligible for inclusion only if the following three criteria were present: a)  
99 they were prospective cohort studies, b) they measured any potential risk factor  
100 within the first month after stroke and c) they measured pain as a key outcome within  
101 one year after stroke. Any definition and measure of pain used by study authors was  
102 deemed acceptable for inclusion. Studies in languages other than English were  
103 included only if a full-text English version could be sourced. To answer the specific  
104 question of risk it was felt essential that there was an element of temporality between  
105 the measurement of the risk factor and the measurement of pain, **consequently**  
106 **correlates of PSSP were beyond the scope of this study**. Studies were therefore  
107 excluded if they were cross-sectional studies in which all measures were taken at a  
108 single time-point (thereby assessing correlation rather than risk). Case reports,  
109 conference abstracts, poster presentations or other studies where the full report was  
110 not available were also excluded.

111

112 Two reviewers (RH and KM) screened the titles and abstracts independently. Full-  
113 text versions of the selected papers were obtained and were assessed against the  
114 inclusion and exclusion criteria by the same reviewers, again independently. Where  
115 there was disagreement a consensus was made through discussion along with the  
116 third reviewer (CK).

117

118 Authors were contacted when articles were lacking sufficient detail to assess the  
119 inclusion criteria. In all cases clarity was sought to understand if baseline measures  
120 were recorded within the first month after stroke. Authors were asked at what point  
121 baseline measures were taken and, to avoid bias, were not given information of the  
122 research question or the inclusion criteria.

123

#### 124 *Data extraction & risk of bias assessment*

125 The main data extracted included all factors that were identified and analysed as  
126 potential risks or where sufficient data were supplied for factors where an odds ratio  
127 (OR) could be calculated. Other data extracted included the aims and methodology  
128 of each study, the period of observation, baseline characteristics of the cohort,  
129 inclusion/exclusion criteria, how pain was defined and measured, the temporal  
130 aspect of baseline and repeated measures, and limitations of the study in relation to  
131 the research question.

132

133 The risk of bias of included studies was independently assessed by two reviewers  
134 (RH and KM) using the Quality in Prognosis Studies (QUIPS) tool.<sup>21</sup> This tool  
135 considers six domains (Study Participation, Study Attrition, Prognostic Factor  
136 Measurement, Outcome Measurement, Study Confounding, and Statistical Analysis  
137 and Reporting) and rates these as having low, moderate or high risk of bias. Any  
138 disagreement between reviewers related to these assessments was resolved  
139 through discussion until a consensus was reached.

140

141 The overall risk of bias was determined *a priori* and judged as: *low* if 4 or more of the  
142 domains were rated low and no domains rated as high, *moderate* if 4 or less  
143 domains were rated low with one domain rated as high or 3 or less domains rated as  
144 low with no high risk domains, and *high* if 2 or more domains were rated as high or if  
145 1 domain was rated as high with no low risk domains.

146

### 147 *Data Synthesis*

148 The articles were described and summarised in a narrative form. Where possible,  
149 raw data were extracted from the original papers to calculate ORs and 95%  
150 confidence intervals (CI) with the intention of pooling these outcomes in meta-  
151 analysis. Where raw data were not available the ORs presented in the original  
152 articles were used.

153

154 Attempts were made to perform meta-analysis when data for a dichotomous variable  
155 were presented in three or more studies. Between-study heterogeneity was  
156 evaluated at face value based on methodological characteristics such as inclusion  
157 criteria and the method of outcome measurement. If there was substantial variation  
158 in the methods used then data were interpreted narratively. When it was possible to  
159 combine data, heterogeneity was assessed using the  $I^2$  statistic, although it is  
160 acknowledged that detecting true heterogeneity with a very small number of studies  
161 is thought to be very difficult.<sup>22</sup>

162

163 All analyses were performed using random effects models to account for the varied  
164 approaches within the studies. Funnel plots to assess for publication bias were not  
165 presented as it was felt that the small number of studies included would limit their  
166 usefulness of this analysis. All analyses were undertaken using the software  
167 package Comprehensive Meta Analysis (V3.3.070) ([www.Meta-Analysis.com](http://www.Meta-Analysis.com)).

168

169

## 170 **Results**

### 171 *Literature Search*

172 The search from the selected databases returned a total of 1,077 articles (**figure 1**).  
173 An additional 31 articles were sourced through hand-searching reference lists from  
174 key articles (n=3) and through search alerts following the initial search (n=28). During  
175 screening 593 were excluded as they clearly did not meet the necessary inclusion  
176 criteria. A further 11 abstracts were discarded as they were found to be poster  
177 presentations or conference abstracts, and one final paper published in Spanish<sup>23</sup>  
178 was excluded as it was not possible to access in English.

179

180 The full text of the remaining 30 articles were assessed in more detail. A further 21  
181 were excluded due to (a) risk factors not been measured within the first month after  
182 stroke,<sup>8,17,24-30</sup> (b) exploring factors correlated with PSSP rather than risk,<sup>15,16,31-36</sup> (c)  
183 retrospective methodologies,<sup>37,38</sup> and (d) studies' aims not exploring risk of  
184 PSSP.<sup>39,40</sup> Authors of four articles were contacted to seek further clarification  
185 regarding the timing of baseline measures. For two of these studies<sup>41,42</sup> the authors

186 were able to confirm that the baseline measures were recorded within the first month  
187 and were included in the review. Of the other two, one author was unable to recall<sup>17</sup>  
188 and one author did not respond.<sup>8</sup> These were therefore excluded.

189

190 **Figure 1.** PRISMA Flow diagram of study selection

191 <insert Figure 1>

192

193 The remaining nine<sup>2,3,41-47</sup> articles were included in the systematic review. Of these,  
194 seven provided sufficient data to calculate ORs on the four risk factors that had  
195 sufficient data to conduct meta-analyses. However, the study by Isaksson et al<sup>43</sup> was  
196 excluded from all meta-analyses as it was thought to be too heterogeneous due to  
197 only including patients with pronounced UL weakness. It was felt that this was a  
198 significant difference from the populations of the other studies and was likely to  
199 significantly skew the analysis.

200

201 *Characteristics of included studies*

202 The nine papers included consisted of eight prospective cohort studies from seven  
203 different countries published between 2003<sup>44</sup> and 2018.<sup>41</sup> A summary of the  
204 characteristics of the included studies is presented in **table 1**. The mean sample size  
205 of the studies was 309 (range: 31-1474). In total 2474 patients were included in the  
206 data synthesis consisting of 1237 (50%) males and 1237 (50%) females. It was not  
207 possible to calculate a combined description of participants' age due to the variation

208 in descriptive statistics provided across studies. Three studies<sup>2,3,45</sup> reported types of  
209 stroke and found that 87% (n=566) patients had an ischaemic stroke. Side of stroke  
210 was reported in four studies<sup>3,45-47</sup>; 54% (n=247) of participants having a left  
211 hemispheric stroke and 46% (n=211) having a right hemispheric stroke.

212

213 **Table 1.** Characteristics of included studies

214 <insert Table 1>

215

216 Three papers<sup>2,3,44</sup> included all stroke patients and took steps to ensure that  
217 participants with communication or cognitive impairments were included by involving  
218 carers or next-of-kin. One paper<sup>43</sup> restricted participants to only those with  
219 pronounced arm weakness limiting the comparability with other studies. Another<sup>47</sup>  
220 explored only patients who had persistent PSSP leading to the loss of two patients  
221 who had pain but were excluded from the final analysis.

222

223 Five studies<sup>2,3,44,46,47</sup> presented prevalence rates or provided sufficient data to  
224 calculate a rate for PSSP at specific time points. Two studies did not present clear  
225 enough data to calculate a true prevalence, and one study looked at a specific  
226 subsection of patients. At baseline (within the first week), data was available on 1672  
227 patients<sup>3,44</sup> and gave a prevalence rate of 16%. This prevalence increased to 21%  
228 (103/483) at four months,<sup>2,3</sup> 24% (293/1235) at 6 months<sup>44,47</sup> and 23% (105/453) at  
229 one year post-stroke.<sup>2,3</sup>

230

231 The nine papers presented data on a total of 54 different factors that were measured  
232 temporally to allow the calculation of risk. Within these, seven were categorised as  
233 *Demographic factors*, 13 as *Co-morbidities*, and 34 as *Clinical assessments and*  
234 *measures (table 1)*.

235

### 236 *Pain Measurement*

237 There were large variations in how pain was defined and measured. Four papers  
238 defined pain as either at rest or during passive or active movement<sup>43,45-47</sup> but none of  
239 these reported how the data was handled when conflicting results between 'at rest'  
240 and 'on movement' were found. Four papers did not specify how they defined  
241 PSSP,<sup>2,41,42,44</sup> and a final paper defined PSSP as any subjective complaint in the  
242 hemiplegic shoulder.<sup>3</sup> Six papers used either the Visual Analogue Scale<sup>2,3,41,42</sup> or the  
243 Numeric Rating Scale<sup>45,47</sup> but only two<sup>42,45</sup> reported a cut-off value to signify who had  
244 and did not have pain. The other three studies<sup>43,44,46</sup> simply reported whether pain  
245 was 'present' or 'absent' to group their cohorts. Four studies assessed for pain using  
246 only subjective reports,<sup>2,43-45</sup> whilst the others combined clinical examination and  
247 history-taking to determine if pain was present.

248

### 249 *Risk of Bias*

250 The risk of bias was assessed using the QUIPS tool and the ratings for each  
251 individual domain can be seen in **figure 2**. The level of agreement between the two

252 assessors (RH and KM) was calculated using the weighted Cohen's kappa statistic  
253 (weighted  $\kappa = 0.68$ ) which corresponded to a substantial degree of agreement.<sup>48</sup>

254

255 Using these domains and *a priori* determined criteria, two studies<sup>2,3</sup> were judged to  
256 have an overall low risk of bias, five studies to be moderate risk of bias,<sup>42-45,47</sup> and  
257 two studies<sup>41,46</sup> to have a high risk of bias overall.

258

259 **Figure 2.** Assessment of risk of bias using the Quality in Prognosis Studies tool

260 <insert Figure 2>

261

262 *Meta-analysis*

263 Only four factors had sufficient data to enable meta-analysis. All analyses were  
264 conducted using a random effects model to account for variations in the approaches  
265 used and samples taken.

266

267 Five studies were included in the analysis of sex. Meta-analysis showed that there  
268 was no difference in the odds for men and women developing PSSP (OR 0.93, CI  
269 95% 0.75-1.15,  $p=0.501$ ) (**figure 3**). The  $I^2$  statistic was very low (0.13%) suggesting  
270 heterogeneity was not present. However, Kontopantelis et al<sup>22</sup> suggest caution when  
271  $I^2$  is so low as it is likely that heterogeneity is present but undetected. Indeed the  
272 wide 95% CI for Roosink et al<sup>47</sup> suggests poor precision and could potentially mask  
273 heterogeneity.

274

275 Four studies were included in the analysis of stroke laterality. Again no statistical  
276 difference was found in relation to whether the stroke was in the right or left  
277 hemisphere (OR 0.78, CI 95% 0.59-1.05,  $p=0.097$ ,  $I^2=9.52\%$ ) (**figure 4**).

278 Interestingly, although not statistically significant, there is a shift of the 95% CI  
279 towards patients with right hemisphere strokes having a slightly increased risk of  
280 PSSP. Further studies would be needed to explore this.

281

282 **Figure 3.** Forest plot displaying the pooled OR analysis for sex

283 <insert Figure 3>

284

285 **Figure 4.** Forest plot displaying the pooled OR analysis for laterality

286 <insert Figure 4>

287

288 The analysis for diabetes included six studies. Meta-analysis showed that diabetic  
289 patients were twice as likely to develop PSSP as patients without diabetes (OR 2.09,  
290 95% CI 1.16-3.78) and that this finding was statistically significant ( $p=0.015$ ).

291 However, there was a high degree of statistical heterogeneity ( $I^2=74.15\%$ ) as can be  
292 seen by the large spread of ORs and 95% CIs seen in **figure 5**.

293

294 Only three studies were available to conduct a meta-analysis for history of shoulder  
295 pain thereby limiting the acceptability of the results. The analysis identified that a  
296 history of shoulder pain increased the risk of developing PSSP (OR 2.78, 95% CI  
297 1.29-5.97) which was significant (p=0.009). Again, as can be seen in **figure 6**, there  
298 was a high level of heterogeneity between studies although an  $I^2$  statistic was not  
299 calculated as it was felt displaying this with the small number of included studies  
300 would provide misleading or inaccurate information. It is also worth noting that two  
301 studies with data were excluded from analysis due to significant variations in their  
302 inclusion criteria. Isaksson et al<sup>43</sup> only included patients with pronounced weakness,  
303 and Roosink et al<sup>47</sup> excluded patients with severe pre-morbid pain. Notably both of  
304 these studies showed non-significant results (**table 3**).

305

306 All other factors were not appropriate for combining in meta-analysis and are  
307 summarised in narrative synthesis below.

308

309 **Figure 5.** Forest plot displaying the pooled OR analysis for diabetes

310 <insert Figure 5>

311

312 **Figure 6.** Forest plot displaying the pooled OR analysis for history of shoulder pain

313 <insert Figure 6>

314

315 *Demographics*

316 The data for demographic data can be viewed in **table 2**. Analyses for age as a risk  
317 factor were inconclusive due the variations in measurement used. One study<sup>45</sup>  
318 reported an increased risk for younger patients (<70 years). However, two other  
319 studies<sup>3,44</sup> found age to be nonsignificant as a predictor of PSSP when used as a  
320 factor in multivariate analysis.

321

322 Four papers reported data on the type of stroke. Isaksson et al<sup>43</sup> reported data that  
323 showed patients with haemorrhagic strokes were more likely to develop PSSP,  
324 however only patients with pronounced weakness were included which could bias  
325 the result. The other three studies<sup>2,3,45</sup> showed no significant difference between  
326 types of stroke as a predictor.

327

328 It was possible to calculate ORs for the subtype of stroke (Oxfordshire classification)  
329 in two papers.<sup>2,3</sup> Only the total anterior circulation stroke was shown to be a  
330 significant risk for developing PSSP at four months when compared with lacunar  
331 strokes.

332

333 One paper<sup>42</sup> considered smoking habits as a potential risk factor but data was not  
334 available to calculate an OR.

335

336 **Table 2.** Demographics - Factors with sufficient data to calculate OR

337 <insert Table 2>

338

339 *Co-morbidities*

340 Diabetes and a history of shoulder pain has been discussed in the meta-analysis. Of  
341 the other co-morbidities with data available for ORs none showed a statistically  
342 significant increased odds of developing PSSP (**table 3**). Temporary  
343 unconsciousness at onset was considered as a risk factor in one paper<sup>42</sup> but data  
344 was not available to calculate an OR.

345

346 **Table 3.** Comorbidities - Factors with sufficient data to calculate OR

347 <insert Table 3>

348

349 *Clinical assessments and measures*

350 The full list of measures and ORs for clinical assessment and measures can be seen  
351 in **table 4**. Severity of upper limb (UL) motor function was concluded to be a major  
352 risk factor in four papers.<sup>2,3,44,45</sup> Unfortunately a variety of outcome measures was  
353 used making comparisons unfeasible. Significant results were found for the odds  
354 ratio of a poor score on item 5 on the National Institutes of Health Stroke Scale ( $\geq 3$ )  
355 for the development of pain within 6 months<sup>45</sup> and within 1 year.<sup>3</sup> This measure was  
356 also shown to be significant ( $p=0.03$ ) in a logistic regression analysis by Lind et al<sup>2</sup>  
357 but no data was supplied to calculate an OR.

358

359 Kim et al<sup>45</sup> also measured motor function using the Fugl-Meyer arm score and found  
360 those patients with lower motor function (a score of 20 or less) were statistically  
361 more likely to develop PSSP at 6 months post-stroke than those with higher scores.

362

363 Ratnasabapathy et al<sup>44</sup> reported an increasing risk of PSSP as UL motor deficit  
364 increased from mild to moderate to severe, suggesting a potential trend. However it  
365 is worth noting that these categories were subjective reports from study participants  
366 and not based on standardised measures.

367

368 It was deemed inappropriate to combine the findings for UL motor function in a meta-  
369 analysis due to the substantial heterogeneity in the method of measurement.

370 However, an impairment in UL motor function at baseline consistently produced a  
371 significantly increased chance of developing PSSP leading to the conclusion that it  
372 was an important risk factor to be aware of.

373

374 Adey-Wakeling et al<sup>3</sup> considered a specific set of shoulder tests (namely the  
375 modified Neer's test, passive hand-behind-neck, and passive external rotation  
376 compared with the unaffected limb) as originally described by Rajaratnam et al.<sup>36</sup>

377 Despite finding that these tests were able to identify a higher frequency of PSSP  
378 than by patient-report, when included in a multivariate analysis the odds ratio was  
379 not significant. This was supported by 2 other studies<sup>45,47</sup> who explored early  
380 reduced range of movement as a predictor for PSSP and found non-significant  
381 results.

382

383 **Table 4.** Clinical assessments and measures - Factors with sufficient data to

384 calculate OR

385 **<insert Table 4>**

386

387 Aspects of somatosensory function including sensation to light touch, sensation to  
388 temperature, sharpness, proprioception, tactile inattention and tactile extinction were  
389 also explored. Only tactile extinction and proprioception were found to significantly  
390 increase the risk of developing PSSP.

391

392 Kim et al<sup>45</sup> presented data on various baseline radiological and sonographic findings  
393 (**table 1**). Readers are directed to the original article to see the full list of ORs for the  
394 factors explored as they are too extensive to be repeated here. Only tendinosis or  
395 tear of the supraspinatus tendon at baseline sonography was associated with PSSP  
396 onset within the first 6 months (OR 4.21, 95% CI 1.37-12.93).

397

398 Data was available to calculate ORs for PSSP at baseline in 2 studies,<sup>3,44</sup> and found  
399 conflicting results. Paci et al<sup>46</sup> did not provide data to calculate an OR but did find  
400 pain at baseline to be significantly associated with pain at follow-up in their multiple  
401 regression analysis ( $p < 0.001$ ), though this was approximately 2 to 3 months after  
402 stroke.

403

404 Across the included studies, it was possible to calculate ORs for a number of other  
405 baseline measures including motor impairment, stroke severity, spasticity in the UL,  
406 subluxation of the glenohumeral joint, dependency during gait, cognition, visual  
407 problems, and autonomic function (**table 4**). These factors were each reported in  
408 only one study and the majority showed no significant relationship to the onset of  
409 PSSP. Only motor impairment (measured using the Motricity Index) and subluxation  
410 showed significant results though the wide 95% CIs for these results would bring into  
411 question the precision of this result.

412

413 Anxiety, depression, communication disorders, and motivation for rehabilitation were  
414 factors considered in one paper<sup>42</sup> but data was not supplied to calculate an OR.

415

416

## 417 **Discussion**

418 This systematic review has identified reduced motor function in the UL, diabetes, and  
419 a history of shoulder pain as risk factors for the development of PSSP within the first  
420 year after stroke. It has also identified a number of clinical assessments made in the  
421 acute stages of stroke that were statistically significant but were only measured in  
422 single studies and lack the benefit of confirmatory evidence. These factors were  
423 reduced motor function, presence of subluxation, tactile extinction and impaired  
424 proprioception.

425

426 The results presented should be interpreted with caution. Care was taken to limit  
427 bias as much as possible by only including prospective studies and by undertaking a  
428 complete and thorough literature search. However, meta-analyses of observational  
429 studies are prone to the biases inherent in the original studies,<sup>49</sup> and unfortunately,  
430 the majority of studies included in this review were rated as a moderate or high risk  
431 of bias. Because of this potential bias, as much of the raw data as was feasible was  
432 included to increase transparency. This was also done so that the reader could make  
433 their own conclusions regarding the weighting each study had on the level of risk for  
434 each factor.

435

436 The likelihood that reduced motor function in the UL leads to an increased risk of  
437 PSSP is unsurprising. The loss of motor function will undoubtedly alter the kinetics  
438 and kinematics around the shoulder complex. This suboptimal performance of  
439 scapula kinesis and the reduced control of forces around the humeral head on the  
440 glenoid has the potential to lead to deleterious effects on anatomical structures  
441 around the shoulder.<sup>50</sup> Indeed, Idowu et al<sup>51</sup> found a significantly higher frequency of  
442 shoulder pathologies in hemiplegic shoulders when compared with unaffected  
443 shoulders and control subjects, whilst Yi et al<sup>52</sup> found a trend towards a higher  
444 prevalence of rotator cuff tears with worsening hemiplegia. Unfortunately, neither of  
445 these studies correlated these sonographic findings with the incidence of pain.

446

447 A more recent prospective study<sup>53</sup> of 121 participants further confirmed the  
448 association of reduced motor function of the UL as a risk factor for PSSP. They also  
449 concluded, in support of Paci et al,<sup>46</sup> that subluxation was an important risk factor

450 and reported a significant proportional difference between those with subluxation  
451 who did and did not have PSSP at the 8-10 week follow up ( $p=0.026$ ). However,  
452 when the data are used to calculate an OR in the same method as this review the  
453 outcome is non-significant (OR 1.68, 95% CI 0.49-5.70). It would seem logical that  
454 subluxation of the glenohumeral joint would lead to similar pathobiomechanics as  
455 previously discussed and thereby also be a risk factor for PSSP. However, further  
456 confirmatory studies with a temporal element to the measurement of risk factors and  
457 pain are required to clarify this.

458

459 The identification of diabetes as a risk factor for PSSP is also unsurprising given the  
460 increased prevalence of shoulder pain in diabetic patients in the general  
461 population.<sup>50</sup> Both tendinopathy<sup>51</sup> and adhesive capsulitis<sup>52</sup> were found to be more  
462 prevalent in patients with diabetes and both of these conditions are a potential  
463 source of PSSP. The increased risk of shoulder pain in diabetic patients is thought to  
464 be due to advanced glycation end-products causing stiffness and weakness in  
465 connective tissues,<sup>53</sup> this, coupled with the reduced function following a stroke, may  
466 further enhance the damaging effects of structures in the shoulder complex.

467

468 This exploratory review has identified a number of factors from the best available  
469 evidence that may aid clinicians in the early identification of patients who may  
470 develop PSSP. Based on these results it is advised that clinicians ensure they  
471 routinely enquire about diabetes and any history of shoulder pain when taking a  
472 patient's medical history. It is not recommended that these findings should be  
473 construed as definitive due to the limitations mentioned hereinafter, however they

474 should be used as a guide to aid clinical reasoning and decision-making when  
475 deciding on which patients to focus preventative strategies. Knowledge of these risk  
476 factors may aid in the understanding of causation and thereby lead to more targeted  
477 prevention strategies. They will also provide clinicians with prognostic information to  
478 better inform patients, carers and relatives.

479

#### 480 *Study Limitations*

481 There were a number of limitations within this systematic review that will impact on  
482 the validity of these results. These limitations were to be expected given the complex  
483 nature of PSSP observed in a clinical setting. Firstly, there were large variations in  
484 the included studies with regards to how pain was defined, how and when risk  
485 factors were measured, and how data were analysed. This has made comparability  
486 between studies very challenging and whilst some data have been combined in  
487 meta-analysis the results should be viewed as informative rather than definitive due  
488 to the heterogeneous nature of the studies included.

489

490 Secondly, due to the large number of potential factors measured, the included  
491 studies may have been limited in what could feasibly be reported, potentially causing  
492 under-reporting or selective reporting of certain variables. Attempts were made to  
493 overcome this potential bias by calculating ORs for all factors where possible,  
494 thereby allowing the recognition of certain risk factors not reported or considered in  
495 the original studies. Whilst calculating crude ORs in this way allowed a larger pool of  
496 data it is recognised that univariate analysis of this type does not take into account  
497 the impact these different factors have on each other thereby potentially leading to  
498 an oversimplification of which factors are associated with PSSP.

499

500 *Recommendations*

501 The current categorisation of PSSP within the literature presents a potential problem.  
502 Whilst it is well documented that PSSP is complex and multifactorial in nature it is  
503 often referred to as a single entity rather than as an umbrella-term for a number of  
504 different aetiologies. This broad definition of PSSP is potentially limiting the  
505 specificity of research trials leading to conflicting results. It is recommended that  
506 future studies should explore improved classification of PSSP subtypes to allow  
507 more accurate links to be made between risk factors and PSSP presentation.

508

509 It is also recommended that future studies exploring risk have a standardised and  
510 comparable approach to the measurement of pain. Whilst it is acknowledged that the  
511 measurement of pain in stroke patients presents some difficulties with regards to  
512 validity and reliability,<sup>58</sup> a vertical numeric rating scale would be the preferred option.  
513 It is also recommended that data for pain at rest and on passive or active movement  
514 is analysed and reported separately to improve comparability. Studies exploring  
515 factors associated with PSSP should also give consideration to, and report on, any  
516 qualitative differences in the nature and pattern of pain between subjects, as well as  
517 factors such as whether the pain was at night or on clinical assessment only.  
518 Observational studies of this nature may help to better understand PSSP subtypes  
519 and improve specificity. Where possible, efforts should be made to ensure the  
520 inclusion of patients with communication or cognitive difficulties by using carers as  
521 proxies when needed to more accurately represent the target population.

522

523 Motor impairment of the upper limb was repeatedly shown to increase the risk of  
524 PSSP, however it was not possible to combine in meta-analysis due to variation in  
525 measurement. This important factor warrants further investigation. In this review the  
526 Fugl-Meyer Assessment was the most credible of the outcome measures used and  
527 would be the authors recommendation for future studies to allow comparative  
528 analysis.

529

530

### 531 **Conclusions**

532 This review has identified motor deficits in the UL, diabetes and a history of shoulder  
533 pain to be significant predictors of the development of PSSP within the first year after  
534 stroke. Whilst it is acknowledged that the lack of robust studies included prevent  
535 definitive conclusions to be made, it is hoped that the results presented will provide  
536 clinicians with a potential 'at risk' group of patients in the acute stage of stroke on  
537 whom to focus preventative strategies. A number of recommendations to standardise  
538 future studies in this area have been made. Future observational studies defining  
539 and categorising the subtypes of PSSP would be beneficial to aid research into the  
540 specificity of treatments for this complex and frequent problem.

541

542

### 543 **Acknowledgements**

544 This research was undertaken as part of a Clinical Improvement Scholarship by Rich Holmes.  
545 Funding for the scholarship was gratefully received from Health Education Kent, Surrey and  
546 Sussex to support backfill costs.

547

548

549 **References**

550

- 551 1. Paolucci S, Iosa M, Toni D, et al. Prevalence and Time Course of Post-Stroke  
552 Pain: A Multicenter Prospective Hospital-Based Study. *Pain Med.*  
553 2016;17(5):924–30.
- 554 2. Lindgren I, Jonsson A-C, Norrving B, Lindgren A. Shoulder pain after stroke: a  
555 prospective population-based study. *Stroke.* 2007;38(2):343–348.
- 556 3. Adey-Wakeling Z, Arima H, Crotty M, Leyden J, Kleinig T, Anderson CS, et al.  
557 Incidence and Associations of Hemiplegic Shoulder Pain Poststroke:  
558 Prospective Population-Based Study. *Archives of Physical Medicine and*  
559 *Rehabilitation.* 2015;96(2):241-247.e1.
- 560 4. Lundström E, Smits A, Terént A, Borg J. Risk factors for stroke-related pain 1  
561 year after first-ever stroke. *European Journal of Neurology.* 2009;16(2):188–93.
- 562 5. Lindgren I, Gard G, Brogårdh C. Shoulder pain after stroke – experiences,  
563 consequences in daily life and effects of interventions: a qualitative study.  
564 *Disability and Rehabilitation.* 2018;40(10):1176–82.

- 565 6. Chae J, Mascarenhas D, Yu DT, et al. Poststroke Shoulder Pain: Its  
566 Relationship to Motor Impairment, Activity Limitation, and Quality of Life.  
567 Archives of Physical Medicine and Rehabilitation. 2007;88(3):298–301.
- 568 7. Adey-Wakeling Z, Liu E, Crotty M, et al. Hemiplegic Shoulder Pain Reduces  
569 Quality of Life After Acute Stroke: A Prospective Population-Based Study.  
570 American Journal of Physical Medicine & Rehabilitation. 2016;95(10):758.
- 571 8. Barlak A, Unsal S, Kaya K, Sahin-Onat S, Ozel S. Poststroke shoulder pain in  
572 Turkish stroke patients: relationship with clinical factors and functional  
573 outcomes. International Journal of Rehabilitation Research. 2009;32(4):309–15.
- 574 9. Viana R, Pereira S, Mehta S, Miller T, Teasell R. Evidence for Therapeutic  
575 Interventions for Hemiplegic Shoulder Pain During the Chronic Stage of Stroke:  
576 A Review. Topics in Stroke Rehabilitation. 2012;19(6):514–22.
- 577 10. Wilson RD, Chae J. Hemiplegic Shoulder Pain. Phys Med Rehabil Clin N Am.  
578 2015;26(4):641–55.
- 579 11. Holmes RJ, Connell LA. A survey of the current practice of intramuscular  
580 Botulinum toxin injections for hemiplegic shoulder pain in the UK. Disability and  
581 Rehabilitation. 2019;41(6):720–6.
- 582 12. Nadler M, Pauls MMH. Shoulder orthoses for the prevention and reduction of  
583 hemiplegic shoulder pain and subluxation: systematic review. Clinical  
584 Rehabilitation. 2017;21(4):444-53.

- 585 13. Qiu H, Li J, Zhou T, Wang H, Li J. Electrical Stimulation in the Treatment of  
586 Hemiplegic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials.  
587 American Journal of Physical Medicine & Rehabilitation. 2019;98(4):280-6.
- 588 14. Li Z, Alexander SA. Current Evidence in the Management of Poststroke  
589 Hemiplegic Shoulder Pain: A Review. Journal of Neuroscience Nursing.  
590 2015;47(1):10-9.
- 591 15. Zorowitz RD, Hughes MB, Idank D, Ikai T, Johnston MV. Shoulder pain and  
592 subluxation after stroke: correlation or coincidence? The American Journal of  
593 Occupational Therapy. 1996;50(3):194–201.
- 594 16. Van Ouwenaller C, Laplace PM, Chantraine A. Painful shoulder in hemiplegia.  
595 Archives of physical medicine and rehabilitation. 1986;67(1):23–26.
- 596 17. Gamble GE, Barberan E, Laasch H-U, Bowsher D, Tyrrell PJ, Jones AK.  
597 Poststroke shoulder pain: a prospective study of the association and risk factors  
598 in 152 patients from a consecutive cohort of 205 patients presenting with stroke.  
599 European journal of pain. 2002;6(6):467–474.
- 600 18. Kalichman L, Ratmansky M. Underlying pathology and associated factors of  
601 hemiplegic shoulder pain. Am J Phys Med Rehabil. 2011;90(9):768–80.
- 602 19. Rajaratnam B. Clinical features associated with hemiplegic shoulder pain: a  
603 systematic review. Physiotherapy Singapore. 2008;11(4):11-17
- 604 20. Moher D. Preferred Reporting Items for Systematic Reviews and Meta-  
605 Analyses: The PRISMA Statement. Ann Intern Med. 2009;151(4):264.

- 606 21. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing  
607 Bias in Studies of Prognostic Factors. *Ann Intern Med.* 2013;158(4):280–6.
- 608 22. Kontopantelis E, Springate DA, Reeves D. A Re-Analysis of the Cochrane  
609 Library Data: The Dangers of Unobserved Heterogeneity in Meta-Analyses.  
610 *PLOS ONE.* 2013;8(7):e69930.
- 611 23. Palazón García R, Alonso Ruiz MT, Martín Márquez J, Berrocal Sánchez I.  
612 Hombro doloroso en el hemipléjico. *Rehabilitación.* 2004;38(3):104–7.
- 613 24. Karaahmet OZ, Eksioglu E, Gurcay E, et al. Hemiplegic Shoulder Pain:  
614 Associated Factors and Rehabilitation Outcomes of Hemiplegic Patients With  
615 and Without Shoulder Pain. *Topics in Stroke Rehabilitation.* 2014;21(3):237–45.
- 616 25. Roosink M, Van Dongen RT, Buitenweg JR, Renzenbrink GJ, Geurts AC,  
617 IJzerman MJ. Multimodal and Widespread Somatosensory Abnormalities in  
618 Persistent Shoulder Pain in the First 6 Months After Stroke: An Exploratory  
619 Study. *Archives of Physical Medicine and Rehabilitation.* 2012;93(11):1968–74.
- 620 26. Lindgren I, Brogårdh C. Poststroke Shoulder Pain and Its Association With  
621 Upper Extremity Sensorimotor Function, Daily Hand Activities, Perceived  
622 Participation, and Life Satisfaction. *PM&R.* 2014;6(9):781–9.
- 623 27. Lindgren I, Lexell J, Jönsson A-C, Brogårdh C. Left-Sided Hemiparesis, Pain  
624 Frequency, and Decreased Passive Shoulder Range of Abduction Are  
625 Predictors of Long-Lasting Poststroke Shoulder Pain. *PM&R.* 2012;4(8):561–8.
- 626 28. Suethanapornkul S, Kuptniratsaikul PS, Kuptniratsaikul V, Uthensut P,  
627 Dajpratha P, Wongwisethkarn J. Post stroke shoulder subluxation and shoulder

- 628 pain: a cohort multicenter study. *Journal of the Medical Association of Thailand*.  
629 2008;91(12):1885–1892.
- 630 29. Datie AM, Cowppli-Bony P, Akani F, Boni EK, Touré G, Kouassi EB.  
631 Complications De L'épaule De L'hémiplégique Vasculaire: Prévalence Et  
632 Facteurs Associés Au Sein D'une Population De Cérébrolésés Vasculaires Au  
633 Chu D'abidjan (Côte D'ivoire). *African Journal of Neurological Sciences*.  
634 2008;27(1):22–31.
- 635 30. Aras MD, Gokkaya NKO, Comert D, Kaya A, Cakci A. Shoulder Pain in  
636 Hemiplegia: Results from a National Rehabilitation Hospital in Turkey. *American*  
637 *Journal of Physical Medicine & Rehabilitation*. 2004;83(9):713.
- 638 31. Gamble GE, Barberan E, Bowsher D, Tyrrell PJ, Jones AK. Post stroke  
639 shoulder pain: more common than previously realized. *European Journal of*  
640 *Pain*. 2000;4(3):313–315.
- 641 32. Niessen MH, Veeger DH, Meskers CG, Koppe PA, Konijnenbelt MH, Janssen  
642 TW. Relationship Among Shoulder Proprioception, Kinematics, and Pain After  
643 Stroke. *Archives of Physical Medicine and Rehabilitation*. 2009;90(9):1557–64.
- 644 33. Lee IS, Shin YB, Moon T-Y, Jeong YJ, Song JW, Kim DH. Sonography of  
645 patients with hemiplegic shoulder pain after stroke: correlation with motor  
646 recovery stage. *American Journal of Roentgenology*. 2009;192(2):W40–W44.
- 647 34. Dromerick AW, Edwards DF, Kumar A. Hemiplegic Shoulder Pain Syndrome:  
648 Frequency and Characteristics During Inpatient Stroke Rehabilitation. *Archives*  
649 *of Physical Medicine and Rehabilitation*. 2008;89(8):1589–93.

- 650 35. Cheng P-T, Lee C-E, Liaw M-Y, Wong M-K, Hsueh T-C. Risk factors of  
651 hemiplegic shoulder pain in stroke patients. *Journal of Musculoskeletal Pain*.  
652 1995;3(3):59–73.
- 653 36. Rajaratnam BS, Venketasubramanian N, Kumar PV, Goh JC, Chan Y-H.  
654 Predictability of Simple Clinical Tests to Identify Shoulder Pain After Stroke.  
655 *Archives of Physical Medicine and Rehabilitation*. 2007;88(8):1016–21.
- 656 37. Blennerhassett JM, Gyngell K, Crean R. Reduced active control and passive  
657 range at the shoulder increase risk of shoulder pain during inpatient  
658 rehabilitation post-stroke: an observational study. *Journal of Physiotherapy*.  
659 2010;56(3):195–9.
- 660 38. Poulin L de C, Barsauskas A, Berenbaum B, et al. Painful shoulder in the  
661 hemiplegic and unilateral neglect. *Arch Phys Med Rehabil*. 1990;71(9):673–6.
- 662 39. Ada L, Preston E, Langhammer B, Canning CG. Profile of upper limb recovery  
663 and development of secondary impairments in patients after stroke with a  
664 disabled upper limb: An observational study. *Physiotherapy theory and practice*.  
665 2018;1–7.
- 666 40. Pong Y-P, Wang L-Y, Wang L, Leong C-P, Huang Y-C, Chen Y-K. Sonography  
667 of the shoulder in hemiplegic patients undergoing rehabilitation after a recent  
668 stroke. *Journal of Clinical Ultrasound*. 2009;37(4):199–205.
- 669 41. Hadianfard M, Taheri P. Association of Post-Stroke Shoulder Pain with Diabetes  
670 Mellitus and Hyperlipidemia. *Physical Medicine, Rehabilitation, and*  
671 *Electrodiagnosis*. 2018;1(1):33–36.

- 672 42. Hadianfard H, Hadianfard M. Predictor factors of hemiplegic sholder pain in a  
673 group of stroke patients. Iranian Red Crescent Medical Journal.  
674 2008;10(3):218–22.
- 675 43. Isaksson M, Johansson L, Olofsson I, Eurenus E. Shoulder pain and  
676 concomitant hand oedema among stroke patients with pronounced arm paresis.  
677 The European Journal of Physiotherapy. 2013;15(4):208–214.
- 678 44. Ratnasabapathy Y, Broad J, Baskett J, Pledger M, Marshall J, Bonita R.  
679 Shoulder pain in people with a stroke: a population-based study. Clinical  
680 rehabilitation. 2003;17(3):304–311.
- 681 45. Kim YH, Jung SJ, Yang EJ, Paik NJ. Clinical and sonographic risk factors for  
682 hemiplegic shoulder pain: a longitudinal observational study. Journal of  
683 rehabilitation medicine. 2014;46(1):81–87.
- 684 46. Paci M, Nannetti L, Taiti P, Baccini M, Pasquini J, Rinaldi L. Shoulder  
685 subluxation after stroke: relationships with pain and motor recovery.  
686 Physiotherapy Research International. 2007;12(2):95–104.
- 687 47. Roosink M, Renzenbrink GJ, Buitenweg JR, Van Dongen RT, Geurts AC,  
688 IJzerman MJ. Persistent shoulder pain in the first 6 months after stroke: results  
689 of a prospective cohort study. Archives of physical medicine and rehabilitation.  
690 2011;92(7):1139–1145.
- 691 48. Landis JR, Koch GG. The measurement of observer agreement for categorical  
692 data. Biometrics. 1977;33(1):159–74.

- 693 49. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of  
694 observational studies. *BMJ*. 1998;316(7125):140–4.
- 695 50. Kibler WB, Sciascia A. The Shoulder at Risk: Scapular Dyskinesis and Altered  
696 Glenohumeral Rotation. *Operative Techniques in Sports Medicine*.  
697 2016;24(3):162–9.
- 698 Thomas SJ, McDougall C, Brown IDM, et al. Prevalence of symptoms and signs of  
699 shoulder problems in people with diabetes mellitus. *Journal of Shoulder and*  
700 *Elbow Surgery*. 2007;16(6):748–51.
- 701 51. Idowu BM, Ayoola OO, Adetiloye VA, Komolafe MA. Sonographic Evaluation of  
702 Structural Changes in Post-Stroke Hemiplegic Shoulders. *Pol J Radiol*.  
703 2017;82:141–8.
- 704 52. Yi Y, Shim JS, Kim K, et al. Prevalence of the Rotator Cuff Tear Increases With  
705 Weakness in Hemiplegic Shoulder. *Ann Rehabil Med*. 2013;37(4):471–8.
- 706 53. Nadler M, Pauls M, Cluckie G, et al. Shoulder Pain after Recent Stroke  
707 (SPARS): Hemiplegic shoulder pain incidence within 72 hours post-stroke and  
708 8-10 week follow-up (NCT 02574000). *Physiotherapy*. 2019;  
709 doi:<https://doi.org/10.1016/j.physio.2019.08.003>
- 710 54. Thomas SJ, McDougall C, Brown IDM, et al. Prevalence of symptoms and signs  
711 of shoulder problems in people with diabetes mellitus. *Journal of Shoulder and*  
712 *Elbow Surgery*. 2007;16(6):748–51.

- 713 55. Ranger TA, Wong AMY, Cook JL, Gaida JE. Is there an association between  
714 tendinopathy and diabetes mellitus? A systematic review with meta-analysis. Br  
715 J Sports Med. 2016;50(16):982–9.
- 716 56. Zreik NH, Malik RA, Charalambous CP. Adhesive capsulitis of the shoulder and  
717 diabetes: a meta-analysis of prevalence. Muscles Ligaments Tendons J.  
718 2016;6(1):26–34.
- 719 57. Goldin Alison, Beckman Joshua A., Schmidt Ann Marie, Creager Mark A.  
720 Advanced Glycation End Products. Circulation. 2006;114(6):597–605.
- 721 58. Tyson SF, Brown P. How to measure pain in neurological conditions? A  
722 systematic review of psychometric properties and clinical utility of measurement  
723 tools. Clinical Rehabilitation. 2014;28(7):669–86.

724

725

## 726 **Legends of Figures and Tables**

727

728 **Figure 1.** PRISMA Flow diagram of study selection

729 **Figure 2.** Assessment of risk of bias using the Quality in Prognosis Studies tool

730 **Figure 3.** Forest plot displaying the pooled OR analysis for sex

731 **Figure 4.** Forest plot displaying the pooled OR analysis for laterality of stroke

732 **Figure 5.** Forest plot displaying the pooled OR analysis for diabetes

733 **Figure 6.** Forest plot displaying the pooled OR analysis for history of shoulder pain

734 **Table 1.** Characteristics of included studies

735 **Table 2.** Demographics - Factors with sufficient data to calculate OR

736 **Table 3.** Comorbidities - Factors with sufficient data to calculate OR

737 **Table 4.** Clinical assessments and measures - Factors with sufficient data to

738 calculate OR

[Click here to view linked References](#)

# 1 **Risk Factors for Post-Stroke Shoulder Pain: A Systematic Review and Meta-** 2 **analysis**

## 3 4 **Abstract**

5 **Objective:** To identify the risk factors identified within one month post-stroke that  
6 predict the onset of post-stroke shoulder pain (PSSP) within the first year after  
7 stroke.

8 **Methods:** Five databases, (AMED, CINAHL, EMBASE, Medline, PubMed) were  
9 searched from inception to April 2019. Prospective cohort studies that measured a  
10 potential risk factor for post-stroke shoulder pain within the first month after stroke  
11 were included. Two authors independently reviewed and selected articles for  
12 inclusion. Risk of bias was assessed using the Quality in Prognosis Studies tool.  
13 Data extracted included raw data for odds ratio (OR) calculations, definition and  
14 measurement of pain, study limitations and baseline characteristics of participants.  
15 The review was conducted following PRISMA guidelines.

16 **Results:** Nine articles were retrieved that met the inclusion criteria, and six  
17 presented data to use in meta-analysis. Fifty-four different factors were identified as  
18 potential risk factors. Meta-analysis was possible for four factors; sex (OR 0.93, CI  
19 0.75-1.15), laterality (OR 0.78, CI 0.59-1.05), diabetes (OR 2.09, CI 1.16-3.78), and  
20 history of shoulder pain (OR 2.78, CI 1.29-5.97). Reduced motor function in the  
21 upper limb was also identified as a significant risk factor through qualitative  
22 synthesis.

23 **Conclusions:** Reduced motor function in the upper limb, diabetes, and a history of  
24 shoulder pain were identified as significant risk factors for the development of PSSP  
25 within the first year after stroke. Recommendations to standardise future studies in  
26 this area have been made and it is suggested that defining subtypes of PSSP may  
27 aid future interventional studies.

28 **Introduction**

29 Post-stroke shoulder pain (PSSP) is a common and often debilitating consequence  
30 of stroke. Wide variations of incidence have been reported in the literature  
31 dependent on the patient cohort and methodology used. Most recent studies have  
32 found an incidence rate of between 18-22% at 3-4 months after stroke onset<sup>1-3</sup> with a  
33 slight reduction at 1 year post-stroke to between 6-21%.<sup>3,4</sup> Lindgren et al<sup>2</sup> reported  
34 that 73% of patients with PSSP reported they had pain daily whilst a further 11%  
35 reported constant pain, and 45% required some form of analgesic medication.

36

37 PSSP is known to negatively impact on a person's ability to carry out activities of  
38 daily living, such as walking and dressing,<sup>2</sup> and limit their ability to participate in  
39 leisure activities.<sup>5</sup> Furthermore it has been shown to be associated with reduced  
40 quality of life<sup>6,7</sup> as well as having a direct impact on mood.<sup>5</sup> Barlak et al<sup>8</sup> also  
41 reported a significantly longer stay in rehabilitation for patients with PSSP.

42

43 There is therefore a need to limit the impact of this common consequence of stroke  
44 through robust prevention strategies and effective treatment modalities. However,  
45 difficulties arise due to the complex and multifactorial nature of PSSP.<sup>9</sup> A large  
46 variety of possible aetiologies are described in the literature including  
47 musculoskeletal disorders such as rotator cuff dysfunction, bursitis, adhesive  
48 capsulitis, and impingement, as well as neurogenic problems such as spasticity,  
49 central hypersensitivity and complex regional pain syndrome.<sup>10</sup> Unsurprisingly this  
50 multitude of aetiologies has led to multiple interventions been suggested in the

51 literature. However, there seems to be little consensus on the implementation of  
52 some of these interventions<sup>11-13</sup> making assessment of their effectiveness difficult. A  
53 review by Li and Alexander<sup>14</sup> supported this when they found the evidence for  
54 treatments of PSSP to be lacking, though this should not be misinterpreted as  
55 evidence that treatments are ineffective.

56

57 The lack of consensus on best management makes prevention all the more  
58 important. However, to prevent PSSP we must first understand which patients are  
59 most at risk so that strategies can be put in place and regular assessments can be  
60 done to monitor any early developments of PSSP and limit the impact in the chronic  
61 stages. To answer this question, a number of often cited studies have explored  
62 factors that are correlated with PSSP such as subluxation,<sup>15</sup> spasticity,<sup>16</sup> and  
63 abnormal joint examination.<sup>17</sup> But due to the lack of repeated temporal measures  
64 these correlations do not show causation and the factors explored should not be  
65 interpreted as risk factors.

66

67 To date, reviews exploring PSSP have either been narrative in nature<sup>18</sup> or have  
68 focussed on factors that are correlated with PSSP.<sup>19</sup> Whilst these give an indication  
69 of factors closely linked to PSSP, they are limited by the variations in methodologies  
70 included and do not give a satisfactory answer to the matter of risk.

71

72 There is, therefore, a need to collate those studies investigating specifically risk and  
73 predictive factors that are effectively assessed and quantified using robust

74 prospective studies to see if there is agreement within the literature. The aim of this  
75 systematic review was to identify the potential risk factors measured within the first  
76 month after stroke that predicted the onset of shoulder pain within the first year after  
77 stroke.

78

79

## 80 **Methods**

81 To complete and report this review the Preferred Reporting Items for Systematic  
82 Reviews and Meta-Analyses (PRISMA) statement<sup>20</sup> was used.

83

### 84 *Search Strategy*

85 The search strategy was designed with the aid of a clinical librarian with input from  
86 the two lead authors (RH/KM). The databases AMED (1985 – April 2019), CINAHL  
87 (1937 – April 2019), EMBASE (1974 – April 2019), Medline (1946 – April 2019), and  
88 PubMed were used with no limitations applied. Variants of ‘stroke’, ‘shoulder pain’,  
89 and ‘risk factors’ were used as keywords and combined in the search strategy. The  
90 full search strategy can be viewed on the International Prospective Register of  
91 Systematic Reviews (PROSPERO: CRD42018110406) where this systematic review  
92 was registered. Further articles were sourced by hand-searching through the  
93 reference lists of key articles. The websites [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and  
94 [www.ukctg.nihr.ac.uk](http://www.ukctg.nihr.ac.uk) were regularly reviewed to check for any ongoing trials that  
95 may be relevant; however no articles were sourced using this method.

96

97 *Study Selection*

98 Studies were eligible for inclusion only if the following three criteria were present: a)  
99 they were prospective cohort studies, b) they measured any potential risk factor  
100 within the first month after stroke and c) they measured pain as a key outcome within  
101 one year after stroke. Any definition and measure of pain used by study authors was  
102 deemed acceptable for inclusion. Studies in languages other than English were  
103 included only if a full-text English version could be sourced. To answer the specific  
104 question of risk it was felt essential that there was an element of temporality between  
105 the measurement of the risk factor and the measurement of pain, consequently  
106 correlates of PSSP were beyond the scope of this study. Studies were therefore  
107 excluded if they were cross-sectional studies in which all measures were taken at a  
108 single time-point (thereby assessing correlation rather than risk). Case reports,  
109 conference abstracts, poster presentations or other studies where the full report was  
110 not available were also excluded.

111

112 Two reviewers (RH and KM) screened the titles and abstracts independently. Full-  
113 text versions of the selected papers were obtained and were assessed against the  
114 inclusion and exclusion criteria by the same reviewers, again independently. Where  
115 there was disagreement a consensus was made through discussion along with the  
116 third reviewer (CK).

117

118 Authors were contacted when articles were lacking sufficient detail to assess the  
119 inclusion criteria. In all cases clarity was sought to understand if baseline measures  
120 were recorded within the first month after stroke. Authors were asked at what point  
121 baseline measures were taken and, to avoid bias, were not given information of the  
122 research question or the inclusion criteria.

123

#### 124 *Data extraction & risk of bias assessment*

125 The main data extracted included all factors that were identified and analysed as  
126 potential risks or where sufficient data were supplied for factors where an odds ratio  
127 (OR) could be calculated. Other data extracted included the aims and methodology  
128 of each study, the period of observation, baseline characteristics of the cohort,  
129 inclusion/exclusion criteria, how pain was defined and measured, the temporal  
130 aspect of baseline and repeated measures, and limitations of the study in relation to  
131 the research question.

132

133 The risk of bias of included studies was independently assessed by two reviewers  
134 (RH and KM) using the Quality in Prognosis Studies (QUIPS) tool.<sup>21</sup> This tool  
135 considers six domains (Study Participation, Study Attrition, Prognostic Factor  
136 Measurement, Outcome Measurement, Study Confounding, and Statistical Analysis  
137 and Reporting) and rates these as having low, moderate or high risk of bias. Any  
138 disagreement between reviewers related to these assessments was resolved  
139 through discussion until a consensus was reached.

140

141 The overall risk of bias was determined *a priori* and judged as: *low* if 4 or more of the  
142 domains were rated low and no domains rated as high, *moderate* if 4 or less  
143 domains were rated low with one domain rated as high or 3 or less domains rated as  
144 low with no high risk domains, and *high* if 2 or more domains were rated as high or if  
145 1 domain was rated as high with no low risk domains.

146

### 147 *Data Synthesis*

148 The articles were described and summarised in a narrative form. Where possible,  
149 raw data were extracted from the original papers to calculate ORs and 95%  
150 confidence intervals (CI) with the intention of pooling these outcomes in meta-  
151 analysis. Where raw data were not available the ORs presented in the original  
152 articles were used.

153

154 Attempts were made to perform meta-analysis when data for a dichotomous variable  
155 were presented in three or more studies. Between-study heterogeneity was  
156 evaluated at face value based on methodological characteristics such as inclusion  
157 criteria and the method of outcome measurement. If there was substantial variation  
158 in the methods used then data were interpreted narratively. When it was possible to  
159 combine data, heterogeneity was assessed using the  $I^2$  statistic, although it is  
160 acknowledged that detecting true heterogeneity with a very small number of studies  
161 is thought to be very difficult.<sup>22</sup>

162

163 All analyses were performed using random effects models to account for the varied  
164 approaches within the studies. Funnel plots to assess for publication bias were not  
165 presented as it was felt that the small number of studies included would limit their  
166 usefulness of this analysis. All analyses were undertaken using the software  
167 package Comprehensive Meta Analysis (V3.3.070) ([www.Meta-Analysis.com](http://www.Meta-Analysis.com)).

168

169

## 170 **Results**

### 171 *Literature Search*

172 The search from the selected databases returned a total of 1,077 articles (**figure 1**).  
173 An additional 31 articles were sourced through hand-searching reference lists from  
174 key articles (n=3) and through search alerts following the initial search (n=28). During  
175 screening 593 were excluded as they clearly did not meet the necessary inclusion  
176 criteria. A further 11 abstracts were discarded as they were found to be poster  
177 presentations or conference abstracts, and one final paper published in Spanish<sup>23</sup>  
178 was excluded as it was not possible to access in English.

179

180 The full text of the remaining 30 articles were assessed in more detail. A further 21  
181 were excluded due to (a) risk factors not been measured within the first month after  
182 stroke,<sup>8,17,24-30</sup> (b) exploring factors correlated with PSSP rather than risk,<sup>15,16,31-36</sup> (c)  
183 retrospective methodologies,<sup>37,38</sup> and (d) studies' aims not exploring risk of  
184 PSSP.<sup>39,40</sup> Authors of four articles were contacted to seek further clarification  
185 regarding the timing of baseline measures. For two of these studies<sup>41,42</sup> the authors

186 were able to confirm that the baseline measures were recorded within the first month  
187 and were included in the review. Of the other two, one author was unable to recall<sup>17</sup>  
188 and one author did not respond.<sup>8</sup> These were therefore excluded.

189

190 **Figure 1.** PRISMA Flow diagram of study selection

191 <insert Figure 1>

192

193 The remaining nine<sup>2,3,41-47</sup> articles were included in the systematic review. Of these,  
194 seven provided sufficient data to calculate ORs on the four risk factors that had  
195 sufficient data to conduct meta-analyses. However, the study by Isaksson et al<sup>43</sup> was  
196 excluded from all meta-analyses as it was thought to be too heterogeneous due to  
197 only including patients with pronounced UL weakness. It was felt that this was a  
198 significant difference from the populations of the other studies and was likely to  
199 significantly skew the analysis.

200

201 *Characteristics of included studies*

202 The nine papers included consisted of eight prospective cohort studies from seven  
203 different countries published between 2003<sup>44</sup> and 2018.<sup>41</sup> A summary of the  
204 characteristics of the included studies is presented in **table 1**. The mean sample size  
205 of the studies was 309 (range: 31-1474). In total 2474 patients were included in the  
206 data synthesis consisting of 1237 (50%) males and 1237 (50%) females. It was not  
207 possible to calculate a combined description of participants' age due to the variation

208 in descriptive statistics provided across studies. Three studies<sup>2,3,45</sup> reported types of  
209 stroke and found that 87% (n=566) patients had an ischaemic stroke. Side of stroke  
210 was reported in four studies<sup>3,45-47</sup>; 54% (n=247) of participants having a left  
211 hemispheric stroke and 46% (n=211) having a right hemispheric stroke.

212

213 **Table 1.** Characteristics of included studies

214 <insert Table 1>

215

216 Three papers<sup>2,3,44</sup> included all stroke patients and took steps to ensure that  
217 participants with communication or cognitive impairments were included by involving  
218 carers or next-of-kin. One paper<sup>43</sup> restricted participants to only those with  
219 pronounced arm weakness limiting the comparability with other studies. Another<sup>47</sup>  
220 explored only patients who had persistent PSSP leading to the loss of two patients  
221 who had pain but were excluded from the final analysis.

222

223 Five studies<sup>2,3,44,46,47</sup> presented prevalence rates or provided sufficient data to  
224 calculate a rate for PSSP at specific time points. Two studies did not present clear  
225 enough data to calculate a true prevalence, and one study looked at a specific  
226 subsection of patients. At baseline (within the first week), data was available on 1672  
227 patients<sup>3,44</sup> and gave a prevalence rate of 16%. This prevalence increased to 21%  
228 (103/483) at four months,<sup>2,3</sup> 24% (293/1235) at 6 months<sup>44,47</sup> and 23% (105/453) at  
229 one year post-stroke.<sup>2,3</sup>

230

231 The nine papers presented data on a total of 54 different factors that were measured  
232 temporally to allow the calculation of risk. Within these, seven were categorised as  
233 *Demographic factors*, 13 as *Co-morbidities*, and 34 as *Clinical assessments and*  
234 *measures (table 1)*.

235

### 236 *Pain Measurement*

237 There were large variations in how pain was defined and measured. Four papers  
238 defined pain as either at rest or during passive or active movement<sup>43,45-47</sup> but none of  
239 these reported how the data was handled when conflicting results between 'at rest'  
240 and 'on movement' were found. Four papers did not specify how they defined  
241 PSSP,<sup>2,41,42,44</sup> and a final paper defined PSSP as any subjective complaint in the  
242 hemiplegic shoulder.<sup>3</sup> Six papers used either the Visual Analogue Scale<sup>2,3,41,42</sup> or the  
243 Numeric Rating Scale<sup>45,47</sup> but only two<sup>42,45</sup> reported a cut-off value to signify who had  
244 and did not have pain. The other three studies<sup>43,44,46</sup> simply reported whether pain  
245 was 'present' or 'absent' to group their cohorts. Four studies assessed for pain using  
246 only subjective reports,<sup>2,43-45</sup> whilst the others combined clinical examination and  
247 history-taking to determine if pain was present.

248

### 249 *Risk of Bias*

250 The risk of bias was assessed using the QUIPS tool and the ratings for each  
251 individual domain can be seen in **figure 2**. The level of agreement between the two

252 assessors (RH and KM) was calculated using the weighted Cohen's kappa statistic  
253 (weighted  $\kappa = 0.68$ ) which corresponded to a substantial degree of agreement.<sup>48</sup>

254

255 Using these domains and *a priori* determined criteria, two studies<sup>2,3</sup> were judged to  
256 have an overall low risk of bias, five studies to be moderate risk of bias,<sup>42-45,47</sup> and  
257 two studies<sup>41,46</sup> to have a high risk of bias overall.

258

259 **Figure 2.** Assessment of risk of bias using the Quality in Prognosis Studies tool

260 <insert Figure 2>

261

262 *Meta-analysis*

263 Only four factors had sufficient data to enable meta-analysis. All analyses were  
264 conducted using a random effects model to account for variations in the approaches  
265 used and samples taken.

266

267 Five studies were included in the analysis of sex. Meta-analysis showed that there  
268 was no difference in the odds for men and women developing PSSP (OR 0.93, CI  
269 95% 0.75-1.15,  $p=0.501$ ) (**figure 3**). The  $I^2$  statistic was very low (0.13%) suggesting  
270 heterogeneity was not present. However, Kontopantelis et al<sup>22</sup> suggest caution when  
271  $I^2$  is so low as it is likely that heterogeneity is present but undetected. Indeed the  
272 wide 95% CI for Roosink et al<sup>47</sup> suggests poor precision and could potentially mask  
273 heterogeneity.

274

275 Four studies were included in the analysis of stroke laterality. Again no statistical  
276 difference was found in relation to whether the stroke was in the right or left  
277 hemisphere (OR 0.78, CI 95% 0.59-1.05,  $p=0.097$ ,  $I^2=9.52\%$ ) (**figure 4**).

278 Interestingly, although not statistically significant, there is a shift of the 95% CI  
279 towards patients with right hemisphere strokes having a slightly increased risk of  
280 PSSP. Further studies would be needed to explore this.

281

282 **Figure 3.** Forest plot displaying the pooled OR analysis for sex

283 <insert Figure 3>

284

285 **Figure 4.** Forest plot displaying the pooled OR analysis for laterality

286 <insert Figure 4>

287

288 The analysis for diabetes included six studies. Meta-analysis showed that diabetic  
289 patients were twice as likely to develop PSSP as patients without diabetes (OR 2.09,  
290 95% CI 1.16-3.78) and that this finding was statistically significant ( $p=0.015$ ).

291 However, there was a high degree of statistical heterogeneity ( $I^2=74.15\%$ ) as can be  
292 seen by the large spread of ORs and 95% CIs seen in **figure 5**.

293

294 Only three studies were available to conduct a meta-analysis for history of shoulder  
295 pain thereby limiting the acceptability of the results. The analysis identified that a  
296 history of shoulder pain increased the risk of developing PSSP (OR 2.78, 95% CI  
297 1.29-5.97) which was significant (p=0.009). Again, as can be seen in **figure 6**, there  
298 was a high level of heterogeneity between studies although an  $I^2$  statistic was not  
299 calculated as it was felt displaying this with the small number of included studies  
300 would provide misleading or inaccurate information. It is also worth noting that two  
301 studies with data were excluded from analysis due to significant variations in their  
302 inclusion criteria. Isaksson et al<sup>43</sup> only included patients with pronounced weakness,  
303 and Roosink et al<sup>47</sup> excluded patients with severe pre-morbid pain. Notably both of  
304 these studies showed non-significant results (**table 3**).

305

306 All other factors were not appropriate for combining in meta-analysis and are  
307 summarised in narrative synthesis below.

308

309 **Figure 5.** Forest plot displaying the pooled OR analysis for diabetes

310 <insert Figure 5>

311

312 **Figure 6.** Forest plot displaying the pooled OR analysis for history of shoulder pain

313 <insert Figure 6>

314

315 *Demographics*

316 The data for demographic data can be viewed in **table 2**. Analyses for age as a risk  
317 factor were inconclusive due the variations in measurement used. One study<sup>45</sup>  
318 reported an increased risk for younger patients (<70 years). However, two other  
319 studies<sup>3,44</sup> found age to be nonsignificant as a predictor of PSSP when used as a  
320 factor in multivariate analysis.

321

322 Four papers reported data on the type of stroke. Isaksson et al<sup>43</sup> reported data that  
323 showed patients with haemorrhagic strokes were more likely to develop PSSP,  
324 however only patients with pronounced weakness were included which could bias  
325 the result. The other three studies<sup>2,3,45</sup> showed no significant difference between  
326 types of stroke as a predictor.

327

328 It was possible to calculate ORs for the subtype of stroke (Oxfordshire classification)  
329 in two papers.<sup>2,3</sup> Only the total anterior circulation stroke was shown to be a  
330 significant risk for developing PSSP at four months when compared with lacunar  
331 strokes.

332

333 One paper<sup>42</sup> considered smoking habits as a potential risk factor but data was not  
334 available to calculate an OR.

335

336 **Table 2.** Demographics - Factors with sufficient data to calculate OR

337 <insert Table 2>

338

339 *Co-morbidities*

340 Diabetes and a history of shoulder pain has been discussed in the meta-analysis. Of  
341 the other co-morbidities with data available for ORs none showed a statistically  
342 significant increased odds of developing PSSP (**table 3**). Temporary  
343 unconsciousness at onset was considered as a risk factor in one paper<sup>42</sup> but data  
344 was not available to calculate an OR.

345

346 **Table 3.** Comorbidities - Factors with sufficient data to calculate OR

347 <insert Table 3>

348

349 *Clinical assessments and measures*

350 The full list of measures and ORs for clinical assessment and measures can be seen  
351 in **table 4**. Severity of upper limb (UL) motor function was concluded to be a major  
352 risk factor in four papers.<sup>2,3,44,45</sup> Unfortunately a variety of outcome measures was  
353 used making comparisons unfeasible. Significant results were found for the odds  
354 ratio of a poor score on item 5 on the National Institutes of Health Stroke Scale ( $\geq 3$ )  
355 for the development of pain within 6 months<sup>45</sup> and within 1 year.<sup>3</sup> This measure was  
356 also shown to be significant ( $p=0.03$ ) in a logistic regression analysis by Lind et al<sup>2</sup>  
357 but no data was supplied to calculate an OR.

358

359 Kim et al<sup>45</sup> also measured motor function using the Fugl-Meyer arm score and found  
360 those patients with lower motor function (a score of 20 or less) were statistically  
361 more likely to develop PSSP at 6 months post-stroke than those with higher scores.

362

363 Ratnasabapathy et al<sup>44</sup> reported an increasing risk of PSSP as UL motor deficit  
364 increased from mild to moderate to severe, suggesting a potential trend. However it  
365 is worth noting that these categories were subjective reports from study participants  
366 and not based on standardised measures.

367

368 It was deemed inappropriate to combine the findings for UL motor function in a meta-  
369 analysis due to the substantial heterogeneity in the method of measurement.

370 However, an impairment in UL motor function at baseline consistently produced a  
371 significantly increased chance of developing PSSP leading to the conclusion that it  
372 was an important risk factor to be aware of.

373

374 Adey-Wakeling et al<sup>3</sup> considered a specific set of shoulder tests (namely the  
375 modified Neer's test, passive hand-behind-neck, and passive external rotation  
376 compared with the unaffected limb) as originally described by Rajaratnam et al.<sup>36</sup>

377 Despite finding that these tests were able to identify a higher frequency of PSSP  
378 than by patient-report, when included in a multivariate analysis the odds ratio was  
379 not significant. This was supported by 2 other studies<sup>45,47</sup> who explored early  
380 reduced range of movement as a predictor for PSSP and found non-significant  
381 results.

382

383 **Table 4.** Clinical assessments and measures - Factors with sufficient data to  
384 calculate OR

385 <insert Table 4>

386

387 Aspects of somatosensory function including sensation to light touch, sensation to  
388 temperature, sharpness, proprioception, tactile inattention and tactile extinction were  
389 also explored. Only tactile extinction and proprioception were found to significantly  
390 increase the risk of developing PSSP.

391

392 Kim et al<sup>45</sup> presented data on various baseline radiological and sonographic findings  
393 (**table 1**). Readers are directed to the original article to see the full list of ORs for the  
394 factors explored as they are too extensive to be repeated here. Only tendinosis or  
395 tear of the supraspinatus tendon at baseline sonography was associated with PSSP  
396 onset within the first 6 months (OR 4.21, 95% CI 1.37-12.93).

397

398 Data was available to calculate ORs for PSSP at baseline in 2 studies,<sup>3,44</sup> and found  
399 conflicting results. Paci et al<sup>46</sup> did not provide data to calculate an OR but did find  
400 pain at baseline to be significantly associated with pain at follow-up in their multiple  
401 regression analysis ( $p < 0.001$ ), though this was approximately 2 to 3 months after  
402 stroke.

403

404 Across the included studies, it was possible to calculate ORs for a number of other  
405 baseline measures including motor impairment, stroke severity, spasticity in the UL,  
406 subluxation of the glenohumeral joint, dependency during gait, cognition, visual  
407 problems, and autonomic function (**table 4**). These factors were each reported in  
408 only one study and the majority showed no significant relationship to the onset of  
409 PSSP. Only motor impairment (measured using the Motricity Index) and subluxation  
410 showed significant results though the wide 95% CIs for these results would bring into  
411 question the precision of this result.

412

413 Anxiety, depression, communication disorders, and motivation for rehabilitation were  
414 factors considered in one paper<sup>42</sup> but data was not supplied to calculate an OR.

415

416

## 417 **Discussion**

418 This systematic review has identified reduced motor function in the UL, diabetes, and  
419 a history of shoulder pain as risk factors for the development of PSSP within the first  
420 year after stroke. It has also identified a number of clinical assessments made in the  
421 acute stages of stroke that were statistically significant but were only measured in  
422 single studies and lack the benefit of confirmatory evidence. These factors were  
423 reduced motor function, presence of subluxation, tactile extinction and impaired  
424 proprioception.

425

426 The results presented should be interpreted with caution. Care was taken to limit  
427 bias as much as possible by only including prospective studies and by undertaking a  
428 complete and thorough literature search. However, meta-analyses of observational  
429 studies are prone to the biases inherent in the original studies,<sup>49</sup> and unfortunately,  
430 the majority of studies included in this review were rated as a moderate or high risk  
431 of bias. Because of this potential bias, as much of the raw data as was feasible was  
432 included to increase transparency. This was also done so that the reader could make  
433 their own conclusions regarding the weighting each study had on the level of risk for  
434 each factor.

435

436 The likelihood that reduced motor function in the UL leads to an increased risk of  
437 PSSP is unsurprising. The loss of motor function will undoubtedly alter the kinetics  
438 and kinematics around the shoulder complex. This suboptimal performance of  
439 scapula kinesis and the reduced control of forces around the humeral head on the  
440 glenoid has the potential to lead to deleterious effects on anatomical structures  
441 around the shoulder.<sup>50</sup> Indeed, Idowu et al<sup>51</sup> found a significantly higher frequency of  
442 shoulder pathologies in hemiplegic shoulders when compared with unaffected  
443 shoulders and control subjects, whilst Yi et al<sup>52</sup> found a trend towards a higher  
444 prevalence of rotator cuff tears with worsening hemiplegia. Unfortunately, neither of  
445 these studies correlated these sonographic findings with the incidence of pain.

446

447 A more recent prospective study<sup>53</sup> of 121 participants further confirmed the  
448 association of reduced motor function of the UL as a risk factor for PSSP. They also  
449 concluded, in support of Paci et al,<sup>46</sup> that subluxation was an important risk factor

450 and reported a significant proportional difference between those with subluxation  
451 who did and did not have PSSP at the 8-10 week follow up ( $p=0.026$ ). However,  
452 when the data are used to calculate an OR in the same method as this review the  
453 outcome is non-significant (OR 1.68, 95% CI 0.49-5.70). It would seem logical that  
454 subluxation of the glenohumeral joint would lead to similar pathobiomechanics as  
455 previously discussed and thereby also be a risk factor for PSSP. However, further  
456 confirmatory studies with a temporal element to the measurement of risk factors and  
457 pain are required to clarify this.

458

459 The identification of diabetes as a risk factor for PSSP is also unsurprising given the  
460 increased prevalence of shoulder pain in diabetic patients in the general  
461 population.<sup>50</sup> Both tendinopathy<sup>51</sup> and adhesive capsulitis<sup>52</sup> were found to be more  
462 prevalent in patients with diabetes and both of these conditions are a potential  
463 source of PSSP. The increased risk of shoulder pain in diabetic patients is thought to  
464 be due to advanced glycation end-products causing stiffness and weakness in  
465 connective tissues,<sup>53</sup> this, coupled with the reduced function following a stroke, may  
466 further enhance the damaging effects of structures in the shoulder complex.

467

468 This exploratory review has identified a number of factors from the best available  
469 evidence that may aid clinicians in the early identification of patients who may  
470 develop PSSP. Based on these results it is advised that clinicians ensure they  
471 routinely enquire about diabetes and any history of shoulder pain when taking a  
472 patient's medical history. It is not recommended that these findings should be  
473 construed as definitive due to the limitations mentioned hereinafter, however they

474 should be used as a guide to aid clinical reasoning and decision-making when  
475 deciding on which patients to focus preventative strategies. Knowledge of these risk  
476 factors may aid in the understanding of causation and thereby lead to more targeted  
477 prevention strategies. They will also provide clinicians with prognostic information to  
478 better inform patients, carers and relatives.

479

#### 480 *Study Limitations*

481 There were a number of limitations within this systematic review that will impact on  
482 the validity of these results. These limitations were to be expected given the complex  
483 nature of PSSP observed in a clinical setting. Firstly, there were large variations in  
484 the included studies with regards to how pain was defined, how and when risk  
485 factors were measured, and how data were analysed. This has made comparability  
486 between studies very challenging and whilst some data have been combined in  
487 meta-analysis the results should be viewed as informative rather than definitive due  
488 to the heterogeneous nature of the studies included.

489

490 Secondly, due to the large number of potential factors measured, the included  
491 studies may have been limited in what could feasibly be reported, potentially causing  
492 under-reporting or selective reporting of certain variables. Attempts were made to  
493 overcome this potential bias by calculating ORs for all factors where possible,  
494 thereby allowing the recognition of certain risk factors not reported or considered in  
495 the original studies. Whilst calculating crude ORs in this way allowed a larger pool of  
496 data it is recognised that univariate analysis of this type does not take into account  
497 the impact these different factors have on each other thereby potentially leading to  
498 an oversimplification of which factors are associated with PSSP.

499

500 *Recommendations*

501 The current categorisation of PSSP within the literature presents a potential problem.  
502 Whilst it is well documented that PSSP is complex and multifactorial in nature it is  
503 often referred to as a single entity rather than as an umbrella-term for a number of  
504 different aetiologies. This broad definition of PSSP is potentially limiting the  
505 specificity of research trials leading to conflicting results. It is recommended that  
506 future studies should explore improved classification of PSSP subtypes to allow  
507 more accurate links to be made between risk factors and PSSP presentation.

508

509 It is also recommended that future studies exploring risk have a standardised and  
510 comparable approach to the measurement of pain. Whilst it is acknowledged that the  
511 measurement of pain in stroke patients presents some difficulties with regards to  
512 validity and reliability,<sup>58</sup> a vertical numeric rating scale would be the preferred option.  
513 It is also recommended that data for pain at rest and on passive or active movement  
514 is analysed and reported separately to improve comparability. Studies exploring  
515 factors associated with PSSP should also give consideration to, and report on, any  
516 qualitative differences in the nature and pattern of pain between subjects, as well as  
517 factors such as whether the pain was at night or on clinical assessment only.  
518 Observational studies of this nature may help to better understand PSSP subtypes  
519 and improve specificity. Where possible, efforts should be made to ensure the  
520 inclusion of patients with communication or cognitive difficulties by using carers as  
521 proxies when needed to more accurately represent the target population.

522

523 Motor impairment of the upper limb was repeatedly shown to increase the risk of  
524 PSSP, however it was not possible to combine in meta-analysis due to variation in  
525 measurement. This important factor warrants further investigation. In this review the  
526 Fugl-Meyer Assessment was the most credible of the outcome measures used and  
527 would be the authors recommendation for future studies to allow comparative  
528 analysis.

529

530

### 531 **Conclusions**

532 This review has identified motor deficits in the UL, diabetes and a history of shoulder  
533 pain to be significant predictors of the development of PSSP within the first year after  
534 stroke. Whilst it is acknowledged that the lack of robust studies included prevent  
535 definitive conclusions to be made, it is hoped that the results presented will provide  
536 clinicians with a potential 'at risk' group of patients in the acute stage of stroke on  
537 whom to focus preventative strategies. A number of recommendations to standardise  
538 future studies in this area have been made. Future observational studies defining  
539 and categorising the subtypes of PSSP would be beneficial to aid research into the  
540 specificity of treatments for this complex and frequent problem.

541

542

### 543 **Acknowledgements**

544 This research was undertaken as part of a Clinical Improvement Scholarship by Rich Holmes.  
545 Funding for the scholarship was gratefully received from Health Education Kent, Surrey and  
546 Sussex to support backfill costs.

547

548

549 **References**

550

- 551 1. Paolucci S, Iosa M, Toni D, et al. Prevalence and Time Course of Post-Stroke  
552 Pain: A Multicenter Prospective Hospital-Based Study. *Pain Med.*  
553 2016;17(5):924–30.
- 554 2. Lindgren I, Jonsson A-C, Norrving B, Lindgren A. Shoulder pain after stroke: a  
555 prospective population-based study. *Stroke.* 2007;38(2):343–348.
- 556 3. Adey-Wakeling Z, Arima H, Crotty M, Leyden J, Kleinig T, Anderson CS, et al.  
557 Incidence and Associations of Hemiplegic Shoulder Pain Poststroke:  
558 Prospective Population-Based Study. *Archives of Physical Medicine and*  
559 *Rehabilitation.* 2015;96(2):241-247.e1.
- 560 4. Lundström E, Smits A, Terént A, Borg J. Risk factors for stroke-related pain 1  
561 year after first-ever stroke. *European Journal of Neurology.* 2009;16(2):188–93.
- 562 5. Lindgren I, Gard G, Brogårdh C. Shoulder pain after stroke – experiences,  
563 consequences in daily life and effects of interventions: a qualitative study.  
564 *Disability and Rehabilitation.* 2018;40(10):1176–82.

- 565 6. Chae J, Mascarenhas D, Yu DT, et al. Poststroke Shoulder Pain: Its  
566 Relationship to Motor Impairment, Activity Limitation, and Quality of Life.  
567 Archives of Physical Medicine and Rehabilitation. 2007;88(3):298–301.
- 568 7. Adey-Wakeling Z, Liu E, Crotty M, et al. Hemiplegic Shoulder Pain Reduces  
569 Quality of Life After Acute Stroke: A Prospective Population-Based Study.  
570 American Journal of Physical Medicine & Rehabilitation. 2016;95(10):758.
- 571 8. Barlak A, Unsal S, Kaya K, Sahin-Onat S, Ozel S. Poststroke shoulder pain in  
572 Turkish stroke patients: relationship with clinical factors and functional  
573 outcomes. International Journal of Rehabilitation Research. 2009;32(4):309–15.
- 574 9. Viana R, Pereira S, Mehta S, Miller T, Teasell R. Evidence for Therapeutic  
575 Interventions for Hemiplegic Shoulder Pain During the Chronic Stage of Stroke:  
576 A Review. Topics in Stroke Rehabilitation. 2012;19(6):514–22.
- 577 10. Wilson RD, Chae J. Hemiplegic Shoulder Pain. Phys Med Rehabil Clin N Am.  
578 2015;26(4):641–55.
- 579 11. Holmes RJ, Connell LA. A survey of the current practice of intramuscular  
580 Botulinum toxin injections for hemiplegic shoulder pain in the UK. Disability and  
581 Rehabilitation. 2019;41(6):720–6.
- 582 12. Nadler M, Pauls MMH. Shoulder orthoses for the prevention and reduction of  
583 hemiplegic shoulder pain and subluxation: systematic review. Clinical  
584 Rehabilitation. 2017;21(4):444-53.

- 585 13. Qiu H, Li J, Zhou T, Wang H, Li J. Electrical Stimulation in the Treatment of  
586 Hemiplegic Shoulder Pain: A Meta-Analysis of Randomized Controlled Trials.  
587 American Journal of Physical Medicine & Rehabilitation. 2019;98(4):280-6.
- 588 14. Li Z, Alexander SA. Current Evidence in the Management of Poststroke  
589 Hemiplegic Shoulder Pain: A Review. Journal of Neuroscience Nursing.  
590 2015;47(1):10-9.
- 591 15. Zorowitz RD, Hughes MB, Idank D, Ikai T, Johnston MV. Shoulder pain and  
592 subluxation after stroke: correlation or coincidence? The American Journal of  
593 Occupational Therapy. 1996;50(3):194–201.
- 594 16. Van Ouwenaller C, Laplace PM, Chantraine A. Painful shoulder in hemiplegia.  
595 Archives of physical medicine and rehabilitation. 1986;67(1):23–26.
- 596 17. Gamble GE, Barberan E, Laasch H-U, Bowsher D, Tyrrell PJ, Jones AK.  
597 Poststroke shoulder pain: a prospective study of the association and risk factors  
598 in 152 patients from a consecutive cohort of 205 patients presenting with stroke.  
599 European journal of pain. 2002;6(6):467–474.
- 600 18. Kalichman L, Ratmansky M. Underlying pathology and associated factors of  
601 hemiplegic shoulder pain. Am J Phys Med Rehabil. 2011;90(9):768–80.
- 602 19. Rajaratnam B. Clinical features associated with hemiplegic shoulder pain: a  
603 systematic review. Physiotherapy Singapore. 2008;11(4):11-17
- 604 20. Moher D. Preferred Reporting Items for Systematic Reviews and Meta-  
605 Analyses: The PRISMA Statement. Ann Intern Med. 2009;151(4):264.

- 606 21. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing  
607 Bias in Studies of Prognostic Factors. *Ann Intern Med.* 2013;158(4):280–6.
- 608 22. Kontopantelis E, Springate DA, Reeves D. A Re-Analysis of the Cochrane  
609 Library Data: The Dangers of Unobserved Heterogeneity in Meta-Analyses.  
610 *PLOS ONE.* 2013;8(7):e69930.
- 611 23. Palazón García R, Alonso Ruiz MT, Martín Márquez J, Berrocal Sánchez I.  
612 Hombro doloroso en el hemipléjico. *Rehabilitación.* 2004;38(3):104–7.
- 613 24. Karaahmet OZ, Eksioglu E, Gurcay E, et al. Hemiplegic Shoulder Pain:  
614 Associated Factors and Rehabilitation Outcomes of Hemiplegic Patients With  
615 and Without Shoulder Pain. *Topics in Stroke Rehabilitation.* 2014;21(3):237–45.
- 616 25. Roosink M, Van Dongen RT, Buitenweg JR, Renzenbrink GJ, Geurts AC,  
617 IJzerman MJ. Multimodal and Widespread Somatosensory Abnormalities in  
618 Persistent Shoulder Pain in the First 6 Months After Stroke: An Exploratory  
619 Study. *Archives of Physical Medicine and Rehabilitation.* 2012;93(11):1968–74.
- 620 26. Lindgren I, Brogårdh C. Poststroke Shoulder Pain and Its Association With  
621 Upper Extremity Sensorimotor Function, Daily Hand Activities, Perceived  
622 Participation, and Life Satisfaction. *PM&R.* 2014;6(9):781–9.
- 623 27. Lindgren I, Lexell J, Jönsson A-C, Brogårdh C. Left-Sided Hemiparesis, Pain  
624 Frequency, and Decreased Passive Shoulder Range of Abduction Are  
625 Predictors of Long-Lasting Poststroke Shoulder Pain. *PM&R.* 2012;4(8):561–8.
- 626 28. Suethanapornkul S, Kuptniratsaikul PS, Kuptniratsaikul V, Uthensut P,  
627 Dajpratha P, Wongwisethkarn J. Post stroke shoulder subluxation and shoulder

- 628 pain: a cohort multicenter study. *Journal of the Medical Association of Thailand*.  
629 2008;91(12):1885–1892.
- 630 29. Datie AM, Cowppli-Bony P, Akani F, Boni EK, Touré G, Kouassi EB.  
631 Complications De L'épaule De L'hémiplégique Vasculaire: Prévalence Et  
632 Facteurs Associés Au Sein D'une Population De Cérébrolésés Vasculaires Au  
633 Chu D'abidjan (Côte D'ivoire). *African Journal of Neurological Sciences*.  
634 2008;27(1):22–31.
- 635 30. Aras MD, Gokkaya NKO, Comert D, Kaya A, Cakci A. Shoulder Pain in  
636 Hemiplegia: Results from a National Rehabilitation Hospital in Turkey. *American*  
637 *Journal of Physical Medicine & Rehabilitation*. 2004;83(9):713.
- 638 31. Gamble GE, Barberan E, Bowsher D, Tyrrell PJ, Jones AK. Post stroke  
639 shoulder pain: more common than previously realized. *European Journal of*  
640 *Pain*. 2000;4(3):313–315.
- 641 32. Niessen MH, Veeger DH, Meskers CG, Koppe PA, Konijnenbelt MH, Janssen  
642 TW. Relationship Among Shoulder Proprioception, Kinematics, and Pain After  
643 Stroke. *Archives of Physical Medicine and Rehabilitation*. 2009;90(9):1557–64.
- 644 33. Lee IS, Shin YB, Moon T-Y, Jeong YJ, Song JW, Kim DH. Sonography of  
645 patients with hemiplegic shoulder pain after stroke: correlation with motor  
646 recovery stage. *American Journal of Roentgenology*. 2009;192(2):W40–W44.
- 647 34. Dromerick AW, Edwards DF, Kumar A. Hemiplegic Shoulder Pain Syndrome:  
648 Frequency and Characteristics During Inpatient Stroke Rehabilitation. *Archives*  
649 *of Physical Medicine and Rehabilitation*. 2008;89(8):1589–93.

- 650 35. Cheng P-T, Lee C-E, Liaw M-Y, Wong M-K, Hsueh T-C. Risk factors of  
651 hemiplegic shoulder pain in stroke patients. *Journal of Musculoskeletal Pain*.  
652 1995;3(3):59–73.
- 653 36. Rajaratnam BS, Venketasubramanian N, Kumar PV, Goh JC, Chan Y-H.  
654 Predictability of Simple Clinical Tests to Identify Shoulder Pain After Stroke.  
655 *Archives of Physical Medicine and Rehabilitation*. 2007;88(8):1016–21.
- 656 37. Blennerhassett JM, Gyngell K, Crean R. Reduced active control and passive  
657 range at the shoulder increase risk of shoulder pain during inpatient  
658 rehabilitation post-stroke: an observational study. *Journal of Physiotherapy*.  
659 2010;56(3):195–9.
- 660 38. Poulin L de C, Barsauskas A, Berenbaum B, et al. Painful shoulder in the  
661 hemiplegic and unilateral neglect. *Arch Phys Med Rehabil*. 1990;71(9):673–6.
- 662 39. Ada L, Preston E, Langhammer B, Canning CG. Profile of upper limb recovery  
663 and development of secondary impairments in patients after stroke with a  
664 disabled upper limb: An observational study. *Physiotherapy theory and practice*.  
665 2018;1–7.
- 666 40. Pong Y-P, Wang L-Y, Wang L, Leong C-P, Huang Y-C, Chen Y-K. Sonography  
667 of the shoulder in hemiplegic patients undergoing rehabilitation after a recent  
668 stroke. *Journal of Clinical Ultrasound*. 2009;37(4):199–205.
- 669 41. Hadianfard M, Taheri P. Association of Post-Stroke Shoulder Pain with Diabetes  
670 Mellitus and Hyperlipidemia. *Physical Medicine, Rehabilitation, and*  
671 *Electrodiagnosis*. 2018;1(1):33–36.

- 672 42. Hadianfard H, Hadianfard M. Predictor factors of hemiplegic sholder pain in a  
673 group of stroke patients. *Iranian Red Crescent Medical Journal*.  
674 2008;10(3):218–22.
- 675 43. Isaksson M, Johansson L, Olofsson I, Eurenus E. Shoulder pain and  
676 concomitant hand oedema among stroke patients with pronounced arm paresis.  
677 *The European Journal of Physiotherapy*. 2013;15(4):208–214.
- 678 44. Ratnasabapathy Y, Broad J, Baskett J, Pledger M, Marshall J, Bonita R.  
679 Shoulder pain in people with a stroke: a population-based study. *Clinical*  
680 *rehabilitation*. 2003;17(3):304–311.
- 681 45. Kim YH, Jung SJ, Yang EJ, Paik NJ. Clinical and sonographic risk factors for  
682 hemiplegic shoulder pain: a longitudinal observational study. *Journal of*  
683 *rehabilitation medicine*. 2014;46(1):81–87.
- 684 46. Paci M, Nannetti L, Taiti P, Baccini M, Pasquini J, Rinaldi L. Shoulder  
685 subluxation after stroke: relationships with pain and motor recovery.  
686 *Physiotherapy Research International*. 2007;12(2):95–104.
- 687 47. Roosink M, Renzenbrink GJ, Buitenweg JR, Van Dongen RT, Geurts AC,  
688 IJzerman MJ. Persistent shoulder pain in the first 6 months after stroke: results  
689 of a prospective cohort study. *Archives of physical medicine and rehabilitation*.  
690 2011;92(7):1139–1145.
- 691 48. Landis JR, Koch GG. The measurement of observer agreement for categorical  
692 data. *Biometrics*. 1977;33(1):159–74.

- 693 49. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of  
694 observational studies. *BMJ*. 1998;316(7125):140–4.
- 695 50. Kibler WB, Sciascia A. The Shoulder at Risk: Scapular Dyskinesis and Altered  
696 Glenohumeral Rotation. *Operative Techniques in Sports Medicine*.  
697 2016;24(3):162–9.
- 698 Thomas SJ, McDougall C, Brown IDM, et al. Prevalence of symptoms and signs of  
699 shoulder problems in people with diabetes mellitus. *Journal of Shoulder and*  
700 *Elbow Surgery*. 2007;16(6):748–51.
- 701 51. Idowu BM, Ayoola OO, Adetiloye VA, Komolafe MA. Sonographic Evaluation of  
702 Structural Changes in Post-Stroke Hemiplegic Shoulders. *Pol J Radiol*.  
703 2017;82:141–8.
- 704 52. Yi Y, Shim JS, Kim K, et al. Prevalence of the Rotator Cuff Tear Increases With  
705 Weakness in Hemiplegic Shoulder. *Ann Rehabil Med*. 2013;37(4):471–8.
- 706 53. Nadler M, Pauls M, Cluckie G, et al. Shoulder Pain after Recent Stroke  
707 (SPARS): Hemiplegic shoulder pain incidence within 72 hours post-stroke and  
708 8-10 week follow-up (NCT 02574000). *Physiotherapy*. 2019;  
709 doi:<https://doi.org/10/1016/j.physio.2019.08.003>
- 710 54. Thomas SJ, McDougall C, Brown IDM, et al. Prevalence of symptoms and signs  
711 of shoulder problems in people with diabetes mellitus. *Journal of Shoulder and*  
712 *Elbow Surgery*. 2007;16(6):748–51.

- 713 55. Ranger TA, Wong AMY, Cook JL, Gaida JE. Is there an association between  
714 tendinopathy and diabetes mellitus? A systematic review with meta-analysis. Br  
715 J Sports Med. 2016;50(16):982–9.
- 716 56. Zreik NH, Malik RA, Charalambous CP. Adhesive capsulitis of the shoulder and  
717 diabetes: a meta-analysis of prevalence. Muscles Ligaments Tendons J.  
718 2016;6(1):26–34.
- 719 57. Goldin Alison, Beckman Joshua A., Schmidt Ann Marie, Creager Mark A.  
720 Advanced Glycation End Products. Circulation. 2006;114(6):597–605.
- 721 58. Tyson SF, Brown P. How to measure pain in neurological conditions? A  
722 systematic review of psychometric properties and clinical utility of measurement  
723 tools. Clinical Rehabilitation. 2014;28(7):669–86.

724

725

## 726 **Legends of Figures and Tables**

727

728 **Figure 1.** PRISMA Flow diagram of study selection

729 **Figure 2.** Assessment of risk of bias using the Quality in Prognosis Studies tool

730 **Figure 3.** Forest plot displaying the pooled OR analysis for sex

731 **Figure 4.** Forest plot displaying the pooled OR analysis for laterality of stroke

732 **Figure 5.** Forest plot displaying the pooled OR analysis for diabetes

733 **Figure 6.** Forest plot displaying the pooled OR analysis for history of shoulder pain

734 **Table 1.** Characteristics of included studies


735 **Table 2.** Demographics - Factors with sufficient data to calculate OR

736 **Table 3.** Comorbidities - Factors with sufficient data to calculate OR

737 **Table 4.** Clinical assessments and measures - Factors with sufficient data to


738 calculate OR


Figure 1. PRISMA Flow diagram of study selection




	Study participation	Study Attrition	Prognostic factor Measurement	Outcome Measurement	Study Confounding	Statistical Analysis & Reporting	Overall risk of bias
Adey-Wakeling (2015)	+	○	+	+	+	+	Low
Kim (2014)	○	-	+	+	+	+	Moderate
Isaksson (2013)	○	+	+	-	○	○	Moderate
Roosink (2011)	-	○	+	+	○	+	Moderate
Paci (2007)	○	○	○	-	○	○	High
Lindgren (2007)	+	○	+	+	+	○	Low
Ratnasabathy (2003)	+	○	-	○	○	○	Moderate
Hadianfard (2018)	○	○	+	○	-	-	High
Hadianfard (2008)	○	○	○	○	○	○	Moderate

+ low  
 ○ moderate  
 - high










Table 1. Characteristics of included studies

Lead author (year)	Country	Study Aims	Sample size	Age	Sex	Eligibility criteria	Risk factors explored:			Time points for follow-up assessments
							Demographics	Comorbidities	Clinical	
Adey-Wakeling (2015)	Australia	Determine frequency, characteristics and determinants of PSSP	226	Mean (SD) 73 (15) in no pain group  72 (14) in shoulder pain group	124M 102F	All patients admitted with diagnosis of stroke  Excluded if subject data ascertained retrospectively, subject denied participation, or deceased	– Age – Sex – Laterality of stroke – Type of stroke – Classification of stroke	– Diabetes mellitus – Previous stroke – Hypertension – Previous MI – History of shoulder pain	– Stroke severity – Arm motor function – Clinical shoulder tests	3 months & 12 months
Hadianfard (2008)	Iran	Explore factors that can predict PSSP	152	Mean 61.2	75M 77F	Any patients admitted with the diagnosis of a stroke  Excluded other causes of hemiplegia and profound cognitive problems	– Age – Sex – Smoking habits	– Temporary unconsciousness in early phase of stroke – History of shoulder pain	– ADLs – Decreased motivation for rehabilitation – Communication disorder – Anxiety – Depression – Decreased visual field – Increased vibration threshold – Increased light touch threshold	Every 2 months upto 12 months
Hadianfard (2018)	Iran	Investigate relationship of diabetes mellitus and hyperlipidemia with PSSP	152	Mean 61.2	75M 77F	Any patients admitted with the diagnosis of a stroke  Excluded other causes of hemiplegia and profound cognitive problems		– Diabetes mellitus – Hypercholesterolaemia – Hypertriglyceridaemia		Every 2 months upto 12 months
Isaksson (2013)	Sweden	Identify clinical factors associated with the development of PSSP in patients with pronounced arm weakness	63	Median 79 (70-86)	26M 37F	Stroke patients with pronounced arm paresis  Excluded palliative care, denied participation, and patients developing centralised pain	– Age – Sex – Laterality of stroke – Type of stroke	– Fall at stroke onset – History of shoulder pain – Previous stroke	– Arm motor function – Gait – Stroke severity	Every 2 weeks until discharge
Kim (2014)	Republic of Korea	To determine baseline risk factors for the occurrence of PSSP during rehabilitation period	94	Mean 65.63 in shoulder pain group  65.49 in no pain group	49M 45F	Acute stroke patients within 1 month confirmed by magnetic resonance imaging  Excluded history of shoulder pain/surgery, recurring or bilateral stroke, severe cognitive impairment, unstable medical condition	– Age – Sex – Laterality of stroke – Type of stroke	– Diabetes mellitus – Hypertension – Cardiovascular disease – Malignancy	– Arm motor function – Sensation to light touch – Reduced range of movement (diagnosed adhesive capsulitis) – Shoulder spasticity – ADLs – Radiological factors (subluxation, acromioclavicular arthropathy, subacromial spur, calcification) – Sonographic factors (supraspinatus, subscapularis and infraspinatus tendinosis/tear, acromioclavicular and glenohumeral degeneration, long head of biceps tendon effusion, subacromial-subdeltoid bursa effusion)	3 months & 6 months
Lindgren (2007)	Sweden	To provide detailed data about PSSP in relation to prevalence, characteristics, influence on daily life, and predictors	327	Mean 73.1	195M 132F	All first-ever strokes included	– Age – Sex – Type of stroke	– Diabetes mellitus – History of shoulder pain	– Stroke severity – Arm motor function	4 months & 12 months

**Table 1. Characteristics of included studies (cont.)**

Lead author (year)	Country	Study Aims	Sample size	Age	Sex	Eligibility criteria	Risk factors explored: Demographics	Comorbidities	Clinical	Time points for follow-up assessments
Paci (2007)	Italy	To study the relationship of shoulder subluxation with PSSP and functional recovery within the first 3 months after stroke	107	Mean (SD) 71.3 (10.5) in subluxed group  72 (9.6) in non-subluxed group	53M 54F	First-ever stroke patients where baseline measures taken within 30 days  Excluded patients with severe, aphasia, severe cognitive impairment, history of shoulder pain/damage and where the diagnosis of subluxation was unclear	– Age – Sex – Laterality of stroke – Time since onset		– ADLs – Sensorimotor impairment – Subluxation	At discharge and 30-40 days post-discharge
Ratnasabathy (2003)	New Zealand	Examine PSSP prevalence and factors associated with its occurrence in the first 6 months after stroke	1474	Only frequency of age ranges given	701M 773F	All strokes included	– Age – Sex – Laterality of stroke	– Diabetes mellitus	– Sensorimotor impairment	1 month & 6 months
Roosink (2011)	The Netherlands	Identify factors associated with persistent PSSP in the first 6 months after stroke	31	Mean (SD) 72 (10) in persistent pain group  65 (13) in no pain group	14M 17F	All first-ever, cortical or sub-cortical unilateral strokes resulting in sensory and/or motor symptoms were eligible  Excluded large amount of patients with comorbidities that could influence pain, pre-morbid arm pain, unable to adequately respond to closed questions, discharged within first 3 days after stroke	– Age – Sex – Laterality of stroke – Handedness – Time since onset	– Diabetes mellitus – TIA – Hypertension – COPD – Obesity – History of shoulder pain	– Motor function – Reduced range of movement – Spasticity of elbow flexors – Subluxation – Impaired sensation (light touch, temperature, sharp, proprioception) – Cognition – Depression – Visual inattention/extinction – Tactile inattention/extinction – Autonomic function	3 months & 6 months

Abbreviations: MI, myocardial infarction; ADLs, activities of daily living; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease.

**Table 2. Demographics - Factors with sufficient data to calculate OR**

Risk factor (exposure group)	Number of participants	Time of follow-up (months)	Method of measurement	OR (95% CI)	
Age (older)	226	within 12	Mean age	0.96 (0.79-1.17) <sup>3</sup>	
	1201	6	10 year increments	1.08 (0.99-1.18) <sup>44</sup>	
	94	within 6	<70, 70 >	0.27 (0.09-0.80) <sup>45</sup>	
Sex (female)	31	6		0.29 (0.06-1.47) <sup>47</sup>	
	327	4		0.82 (0.48-1.41) <sup>2</sup>	
	1201	6		0.91 (0.69-1.19) <sup>44</sup>	
	226	within 12		1.03 (0.77-1.37) <sup>3</sup>	
	94	within 6		1.56 (0.69-3.54) <sup>45</sup>	
Type of stroke (haemorrhagic)	327	4	Imaging	0.75 (0.30-1.89) <sup>2</sup>	
	94	within 6		0.80 (0.30-2.16) <sup>45</sup>	
	226	within 12		1.07 (0.39-2.91) <sup>3</sup>	
	63	not stated		6.25 (1.1-35.6) <sup>43</sup>	
Stroke subtype	226	within 12	Oxfordshire classification	LACS	Reference
				POCS	0.77 (0.41-1.42) <sup>3</sup>
				PACS	0.78 (0.49-1.24) <sup>3</sup>
				TACS	1.28 (0.74-2.24) <sup>3</sup>
	327	4		LACS	Reference
				POCS	0.56 (0.22-1.41) <sup>2</sup>
				PACS	0.64 (0.32-1.29) <sup>2</sup>
TACS	5.19 (2.34-11.51) <sup>2</sup>				
Laterality (left hemisphere)	63	not stated	Imaging	0.51 (0.17-1.48) <sup>43</sup>	
	1008	6		0.69 (0.51-0.92) <sup>44</sup>	
	226	within 12		0.87 (0.65-1.17) <sup>3</sup>	
	31	6		0.88 (0.17-4.49) <sup>47</sup>	
Handedness (right)	31	6	Subjective report	1.26 (0.11-14.05) <sup>47</sup>	

Abbreviations: LACS, lacunar syndrome; POCS, posterior circulation syndrome; PACS, partial anterior circulation syndrome; TACS, total anterior circulation syndrome.

**Table 3. Comorbidities - Factors with sufficient data to calculate OR**

Risk factor (exposure group)	Number of participants	Time of follow-up (months)	OR (95% CI)
Diabetes Mellitus	226	within 12	1.2 (0.62-2.30) <sup>3</sup>
	1201	6	1.52 (1.07-2.17) <sup>44</sup>
	327	4	1.81 (0.92-3.56) <sup>2</sup>
	31	6	8.00 (1.13-56.79) <sup>47</sup>
	152	within 12	8.77 (3.72-20.65) <sup>41</sup>
TIA	31	6	0.29 (0.01-6.27) <sup>47</sup>
Previous stroke	63	not stated	0.42 (0.12-1.49) <sup>43</sup>
	26	within 12	0.47 (0.21-1.07) <sup>3</sup>
Previous MI	226	within 12	1.16 (0.53-2.54) <sup>3</sup>
Hypertension	31	6	0.18 (0.02-1.71) <sup>47</sup>
	94	within 6	0.87 (0.39-1.99) <sup>45</sup>
	226	within 12	0.96 (0.50-2.54) <sup>3</sup>
History of shoulder pain	327	4	1.47 (0.81-2.67) <sup>2</sup>
	31	6	1.63 (0.27-9.98) <sup>47</sup>
	63	not stated	1.64 (0.56-4.74) <sup>43</sup>
	1201	6	2.43 (1.54-3.84) <sup>44</sup>
	226	within 12	8.09 (3.16-20.80) <sup>3</sup>
Fall at onset	63	not stated	1.79 (0.61-5.21) <sup>43</sup>
Obesity	31	6	1.25 (0.10-15.80) <sup>47</sup>
COPD	31	6	0.56 (0.05-5.86) <sup>47</sup>
Hyperlipidaemia	152	within 12	0.80 (0.35-1.83) <sup>41</sup>
Hypertriglyceridaemia	152	within 12	1.39 (0.64-3.02) <sup>41</sup>
Malignancy	94	within 6	0.48 (0.11-2.11) <sup>45</sup>

Abbreviations; TIA, transient ischaemic attack; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease.

**Table 4. Clinical assessments and measures - Factors with sufficient data to calculate OR**

Risk factor (exposure group)	Number of participants	Time of follow-up (months)	Method of measurement	OR (95% CI)	
Stroke severity	226	within 12	NIHSS	1.39 (0.78-2.49) <sup>3</sup>	
Arm motor function (reduced)	73	3	NIHSS (Question 5)	3.08 (1.29-7.38) <sup>45</sup>	
	58	6		3.67 (1.55-8.70) <sup>45</sup>	
	226	within 12	Fugl-Meyer arm score	2.81 (1.40-5.61) <sup>3</sup>	
	73	3		2.72 (1.14-6.49) <sup>45</sup>	
	58	6		3.59 (1.52-8.45) <sup>45</sup>	
Motor function (reduced)	31	6	Motricity index	25.00 (2.27-275.71) <sup>47</sup>	
Sensorimotor impairment	1201	6	Subjective report	None	Reference
				Mild	2.44 (1.73-3.45) <sup>44</sup>
				Moderate	3.72 (2.38-5.82) <sup>44</sup>
				Severe	6.25 (4.15-9.43) <sup>44</sup>
Motor evoked potential (no response)	73	3	EMG	4.09 (1.34-12.40) <sup>45</sup>	
	58	6		2.20 (0.84-5.76) <sup>45</sup>	
Sensation (abnormal light touch)	73	3	NS	1.55 (0.66-3.61) <sup>45</sup>	
	58	6		1.18 (0.52-2.66) <sup>45</sup>	
	31	6	Cotton wool	1.67 (0.35-8.04) <sup>47</sup>	
Sensation (abnormal cold sensation)	31	6	Metal tuning fork	2.67 (0.52-13.70) <sup>47</sup>	
Sensation (abnormal sharp sensation)	31	6	S-W filament	6.00 (0.63-57.00) <sup>47</sup>	
Proprioception (impaired)	31	6	Thumb JPS	6.4 (1.16-35.40) <sup>47</sup>	
Tactile inattention (impaired)	31	6	Uni- & bilateral stimuli	2.26 (0.04-123.00) <sup>47</sup>	
Tactile extinction (impaired)	31	6	Uni- & bilateral stimuli	7.60 (1.06-54.10) <sup>47</sup>	
Pain at baseline (present)	226	within 12	Subjective report	1.57 (0.29-8.45) <sup>3</sup>	
	1201	6		2.20 (1.61-3.01) <sup>44</sup>	
Spasticity (present)	73	3	Modified Ashworth Scale	0.86 (0.27-2.77) <sup>45</sup>	
	58	6		2.79 (0.87-8.92) <sup>45</sup>	
ADLs (reduced)	73	3	Barthel index	1.40 (0.59-3.34) <sup>45</sup>	
	58	6		1.28 (0.56-2.94) <sup>45</sup>	
Shoulder assessment tests (positive)	226	within 12	Neer's test, PHBN, PER	2.10 (0.54-8.35) <sup>3</sup>	

ROM (reduced)	73	3	Goniometry	1.75 (0.75-4.09) <sup>45</sup>
	58	6		1.29 (0.57-2.92) <sup>45</sup>
	31	6	NS	6.00 (0.47-76.70) <sup>47</sup>
Subluxation (present)	107	Approx 2-3	Palpation	28.93 (10.11-82.71) <sup>46</sup>
Gait (immobile)	63	Approx 1-2	FAC	2.11 (0.22-20.12) <sup>43</sup>
Cognition (impaired)	31	6	MMSE	2.71 (0.31-23.1) <sup>47</sup>
Visual field (impaired)	31	6	Uni- & bilateral stimuli	2.71 (0.31-23.10) <sup>47</sup>
Visual extinction (impaired)	31	6	Uni- & bilateral stimuli	3.00 (0.47-19.00) <sup>47</sup>
Autonomic Dysfunction (present)	31	6	Trophic changes	3.40 (0.62-18.80) <sup>47</sup>

Abbreviations: NIHSS, National Institutes of Health Stroke Scale; EMG, electromyography; NS, not stated; S-W, Semmes-Weinstein; JPS, joint position sense; ADLs, activities of daily living; PHBN, passive hand-behind-neck; PER, passive external rotation; ROM, range of movement; FAC, Functional Ambulation Classification; MMSE, Mini-Mental State Examination.